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ABSTRACT 
 
 
The use of agents targeting EGFR represents a new frontier in colon cancer therapy. Among these, 
monoclonal antibodies (mAbs) and EGFR tyrosine kinase inhibitors (TKIs) seemed to be the most 
promising. However they have demonstrated low utility in therapy, the former being effective at 
toxic doses, the latter resulting inefficient in colon cancer. This thesis work presents studies on a 
new EGFR inhibitor, FR18, a molecule containing the same naphtoquinone core as shikonin, an 
agent with great anti-tumor potential. In HT-29, a human colon carcinoma cell line, flow cytometry, 
immunoprecipitation, and Western blot analysis, confocal spectral microscopy have demonstrated 
that FR18 is active at concentrations as low as 10 nM, inhibits EGF binding to EGFR while leaving 
unperturbed the receptor kinase activity. At concentration ranging from 30 nM to 5 µM, it activates 
apoptosis. FR18 seems therefore to have possible therapeutic applications in colon cancer. 
In addition, surface plasmon resonance (SPR) investigation of the direct EGF/EGFR complex 
interaction using different experimental approaches is presented. A commercially available purified 
EGFR was immobilised by amine coupling chemistry on SPR sensor chip and its interaction to EGF 
resulted to have a KD = 368 ± 0.65 nM. SPR technology allows the study of biomolecular 
interactions in real-time and label-free with a high degree of sensitivity and specificity and thus 
represents an important tool for drug discovery studies. On the other hand EGF/EGFR complex 
interaction represents a challenging but important system that can lead to significant general 
knowledge about receptor-ligand interactions, and the design of new drugs intended to interfere 
with EGFR binding activity.  
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1.1 INTRODUCTION TO CANCER 
 
Cancer is a heterogeneous group of diseases in which a single cell, following mutations of genes 
that control cell growth, genetic stability and sensitivity to programmed cell death, acquires the 
ability to proliferate abnormally resulting in an accumulation of progeny. Usually, the mutation 
arises as a result of environmental factors such as chemicals, radiation or viruses and less than 10% 
of all cancer mutations are inherited.  
Cancer is, in essence, a genetic disease that originates through a multistep process. In this model, 
the first stage, the initiation, is caused by the acquisition in a cell of a mutation that can provide a 
growth advantage and/or irreversible alterations in cellular homeostasis and differentiation. Three 
important steps involved in initiation are carcinogens (very often chemical agents), DNA repair, and 
cell proliferation. Many chemical agents must be metabolically activated before they become 
carcinogenic and most of them are strong electrophiles and bind to DNA to form adducts that must 
be removed by DNA repair mechanisms. Hence, DNA repair is essential to reverse adduct 
formation and to prevent DNA damage. Failure to repair chemical adducts, followed by cell 
proliferation, results in permanent alterations or mutation(s) in the genome that can lead to 
oncogene activation or inactivation of tumor suppressor genes. Proto-oncogenes encode proteins 
that promote cell growth, thus their alteration can result in the expression of a protein with impaired 
function or in abnormal expression (typically an over expression) of the normal protein that 
determines a continuous stimulation of cell proliferation. The products of tumor suppressor genes, 
instead, inhibit the uncontrolled proliferation and the damage of both normal alleles is necessary for 
the neoplastic transformation.  
The next step, the promotion, can be a potentially reversible or interruptible clonal expansion of the 
initiated cell by a combination of growth stimulation and inhibition of apoptosis. Further 
progression steps occur upon clonal expansion of the initial cells and accumulation of a sufficient 
number of mutations and epigenetic alterations to acquire growth stimulus-independency and 
resistance to growth inhibitors and apoptosis, ultimately leading to an unlimited replicative 
potential. The acquisition of the ability to invade the surrounding tissue defines the malignant 
character of cancer cells, while the process through which cells can migrate to distal organs and 
acquire the potential to form metastasis represents the achievement of a full malignant cancerous 
phenotype. 
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1.2 COLORECTAL CANCER (CRC) 
 
Colorectal cancer is the third most common cancer in both men and women [1]. It remains one of 
the most frequent and deadly diseases despite important advantages in treatment and diagnosis. The 
most prominent risk factors for CRC are represented by obesity, physical inactivity, alcoholism, 
smoking, and a diet that is high in fats or low in fruits and vegetables [2]. Environmental factors 
presumably modulate the risk for genetic mutations responsible for CRC, although the precise 
molecular mechanisms currently are unknown. The evolution from normal colonic mucosa to 
adenoma with different grades of dysplasia and finally to invasive cancer (adenoma-to-carcinoma 
sequence) is associated with a series of genetic events occurring over an 8- to 11-year time frame 
[3]. Not surprisingly, the incidence of colorectal cancer increases with age, especially after 60 years 
[4]. There appears to be an acceleration of this process in familial adenomatous polyposis (FAP) 
and hereditary nonpolyposis CRC (HNPCC), the two major forms of hereditary CRC.  
FAP makes up 1%-2% of hereditary CRC [5], and arises from genetic mutations in the 
adenomatous polyposis coli (APC) gene, whose protein end product plays a key role in the     
Wnt/β-catenin signaling pathway. HNPCC accounts for approximately 5%-8% of the hereditary 
forms of CRC, and it is caused by genetic mutations in the family of mismatch repair (MMR) 
genes, which include MLH1, MSH2, MSH6, and PMS2 that preserve genomic integrity. In fact, 
germline mutations in one of these four MMR genes have been identified in up to 80% of affected 
families [6]. 
In contrast to hereditary CRC, which makes up approximately 8%-15% of all cases of CRC, 
sporadic CRC accounts for nearly 85%-90% of cases. The significant insights gained from studying 
inherited CRC, however, have contributed greatly to the current understanding of sporadic disease. 
 
 
1.2.1 Histopathology of colorectal cancer development 
 
The digestive surface of the human large intestine is characterized by a monolayer of specialized 
epithelial cells that forms invaginations called crypts. At the base of each crypt 4-6 intestinal stem 
cells are located from which the four cellular types that constitute the intestinal layer originate: 
columnar absorptive cells, the mucussecreting goblet cells, the neuroepithelial cells and the Paneth 
cells. By asymmetrical division, these stem cells are able to renew the complete layer in 3-8 days.  
 
 8 
 
Figure 1.2.1: Morphology of normal colon tissue (cross section). Surface epithelium (SE), colon crypts (CC), goblet 
cells (GC), lamina propria (LP), and muscularis mucosa (MM). Figure has been reproduced from [7]. 
 
 
The first recognisable manifestation of epithelial alteration during colorectal tumor development are 
the aberrant crypt foci (ACF), small hyper- or dysplastic lesions characterized by: 1) bigger size 
than the normal crypts; 2) increased pericryptal space that separates them from the normal crypts; 3) 
a thicker layer of epithelial cells that often stains darker compared with normal crypts; 4) generally 
oval rather than circular openings. The ACF can be observed as single altered crypts or as a group 
of altered crypts that appears to form a single unit or focus. They frequently are microscopically 
elevated above the mucosa but also may be depressed, i.e., they usually are not in the same focal 
plane as the surrounding normal crypts [8, 9]. 
From a practical perspective, although only a small number of ACF will ultimately progress to 
CRC, larger ACF with altered morphology, dysplastic histology and associated gene mutations 
remain high-risk candidates for adenoma and CRC formation [10].  
Upon increase of birth/loss ratio among epithelial cell, their progressive accumulation results in a 
benign tumor mass or polyp (abnormal accumulation of cells). In the intestine, a tumor is clinically 
recognized as a protrusion into the lumen from the wall. From a histological perspective, there are 
at least two major types of polyps: the hyperplastic or non-neoplastic polyp and the dysplastic or 
adenomatous polyp. Whether the first kind of lesion consists of large number of cells with a normal 
morphology that line up in a single row, the adenomatous polyp is represented by abnormal cells 
which show intracellular and intercellular irregularities, with disruption of normal tissue 
architecture. The nuclei of these cells are often hyperchromatic and larger in size than in normal 
intestinal cells, with irregular positioning along the crypt-villus axis due to loss of cell polarity and 
nuclear stratification. Several layers of these abnormal cells give rise to branching glands on the 
lamina propria (the connective tissue layer that supports the epithelium). According to their 
architecture, adenomas may be divided in tubular, when coarsely lobulated and pedunculated, or 
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villous, when sessile, covering a broad area directly onto the muscularis mucosae (the muscle layer 
underlying the epithelial lining) and submucosa (the underlying stromal layer). Villous adenomas 
are thought to have higher risk of malignant progression [11].  
When an adenoma progresses, more undifferentiated cells appear, with a marked pleomorphism 
(variation in size and shape) and a nuclear:cytoplasm ratio close to 1. Moreover, tumor cells show 
aberrant orientations and grow in disorganized fashion. These lesions can also be referred to as 
carcinoma in situ, i.e. advanced high dysplastic lesions still confined within the epithelial layer. 
Finally, malignant adeno-carcinomas are characterized by the ability to invade the surrounding 
tissues through the muscularis mucosae and into the stromal compartment, and migrate to distal 
organs (e.g. the liver) where they can form metastasis [12]. 
The development of carcinoma from adenomatous lesions, also referred as adenoma-to-carcinoma 
sequence, is substantiated by a number of epidemiologic, clinical, pathologic, and molecular genetic 
observations. First, the peak of incidence of adenomatous polyps precedes by some years that of 
colorectal cancer; secondly, small carcinomatous foci are found within advanced adenomatous 
polyps [13]. Also, cancer risk is directly related to the number of adenomas, as shown by the very 
high incidence of carcinoma in patients with >100 polyps such familial adenomatous polyposis 
[14]. 
 
 
1.2.2 Biology of colorectal cancer  
 
The stepwise progression from normal to dysplastic epithelium and to carcinoma is earmarked by 
specific genetic alterations at known proto-oncogenes and tumor suppressor genes. This molecular 
pathway to colorectal cancer is triggered within a single cell that acquires a genetic alteration that 
provides it with a specific type of growth survival advantage. Loss of function mutations at the APC 
tumor suppressor gene on chromosome 5q21 occur in over 80% of colon adenocarcinomas [15], 
thus representing the earliest and rate-limiting genetic event in colorectal tumor initiation [16]. 
Indeed, APC mutations are present already at the ACF stage and they are related with the degree of 
dysplasia of these early lesions [17, 18]. It has been shown that APC’s main tumor suppressor 
activity resides in its capacity to regulate intracellular levels of β-catenin [19, 20, 21], a key member 
of the Wnt signal transduction pathway, which thanks to complex formation with the transcription 
factor TCF/LEF leads to transcriptional activation of target genes such as c-Myc and Cyclin D. 
Mutations of other members of the Wnt pathway, including β-catenin, Axin-1 and Conductin (Axin-
2) have also been found in colorectal cancers [22, 23, 24]. The inactivation of both alleles of the 
APC gene can be detected in most of the intestinal tumors at early stages of development [16, 25], 
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in agreement with Knudson's two hit hypothesis [26]. However, APC second mutational hits are not 
randomly selected, but distributed according to the resulting levels of residual β-catenin           
down-regulating activity [27, 28]. In the situation in which a germline mutation is inherited or 
spontaneously occurred as in the FAP syndrome, the rate of initiation of colonic polyps is 
dramatically increased with the development of thousands of colorectal adenomas and the inevitable 
progression of some of these into carcinoma, unless the intestine is not surgically resected. 
Activation of the KRAS oncogene represents the second step in the evolution towards colorectal 
cancer. The proto-oncogene KRAS encodes a 21 kDa protein that binds guanine nucleotides and is 
localized on the inner cell membrane. The identification of KRAS mutations has been the first major 
breakthrough in the molecular genetic analysis of colorectal cancer [29]. KRAS mutations are found 
in at least 50% of colorectal adenomas larger than 1 cm and in carcinomas but are infrequent in 
adenomas smaller than 1 cm in size [30], indicating a role in adenoma progression rather than 
initiation. Alternatively, mutations in other oncogenes like BRAF encoding for members of the 
same RAS pathway, are often found among adenomas [31]. KRAS mutations affect only specific 
codons (12, 13, 59-61) relevant for the endogenous guanine triphosphatase activity, leading to the 
constitutive activation of the Ras/Raf/MEK/ERK signal transduction pathway. Activation of this 
signaling pathway results in the transduction, from the surface receptors (such as epidermial growth 
factor receptor, EGFR), to the nucleus of signals for the transcriptional activation of target genes 
involved in cell proliferation and apoptosis inhibition like Cyclin-dependent kinases, Cyclins and 
Bcl-2 [32] and thus malignant transformation. 
Further malignant progression is accompanied by loss of all or part of the long arm of chromosome 
18 (18q). At least 50% of large adenomas and 75% of carcinomas show loss of heterozygosity 
(LOH) at chromosome 18q [30, 33, 34]. The first candidate tumor suppressor gene in this 
chromosomal interval, the "deleted in colorectal cancer" gene (DCC), has been identified as a 
component of a receptor complex that mediates axon guidance in neurons [35]. However DCC 
mutations are rarely found in colorectal cancers [36].  
Other tumor suppressor genes have been subsequently identified in this region and, among others, 
two intracellular mediators of the TGF-β signal transduction pathway SMAD2 and SMAD4. Binding 
of TGF-β to the TGFBR2 receptor promotes the formation of heterodimer with the TGFBR1 
receptor and phosphorylation of members of the SMAD family of intracellular mediators like 
SMAD2. Activated SMAD2 binds SMAD4 with its consequent nuclear translocation where the 
complex activates the transcription of genes responsible for a broad spectrum of cellular functions 
such as cellular growth inhibition, apoptosis, differentiation, and matrix production [37, 38]. Thus, 
when SMAD2 or SMAD4 are mutated, TGF-β signal is not transduced into the nucleus of the cell. 
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TGFBR2 mutations are also frequently found to affect TGF-β signaling in CRC. Overall, there is 
convincing mutational evidence for the major role of TGF-β pathway inactivation in the     
adenoma-to-carcinoma transition and, more in general, as primary tumor suppressor in human 
colorectal carcinogenesis. 
Most malignant colorectal tumors are also characterized by loss of the short arm of chromosome 17 
(17p). LOH or cytogenetic alterations at this locus correlate with the transition from benign 
adenoma to invasive cancer [30, 39, 40]. The TP53 gene, encoding for p53, maps to this 
chromosomal interval. p53 is a multifunctional protein essential to cell growth control [41] often 
regarded to as the "guardian of the genome" due to his ability to block cell proliferation via 
transcriptional activation of cell cycle inhibitors, like p21, in the presence of DNA damage [42]. 
p53 also promotes apoptosis via transcriptional activation of genes such as BAX in situations where 
the DNA repair machinery cannot cope with the DNA damage load [43]. p53 alterations, often 
measured as aberrant overexpression in immunohistochemical assays, by direct DNA sequencing or 
by 17p allelic loss, have been reported in 4-26% of adenomas, approximately 50% of in situ 
carcinomas, and in 50-75% of adenocarcinoma   [44, 45, 46, 47, 48]. The latter is indicative of the 
central role of loss of p53 function in the adenoma to carcinoma transition. 
Figure 1.2.2 summarizes the accumulation of gene alterations in different pathways involved the 
CCR pathogenesis starting from normal epithelium. 
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Figure 1.2.2: Schematic representation of the accumulation of alterations in different pathways along the               
adenoma-carcinoma sequence. In red are shown the genes frequently mutated in CRC. The different cellular alterations 
resulting from the accumulations of these signaling defects are listed in the right column. EMT, epithelial to 
mesenchymal transitions, contributes to local invasion and distant cancer metastasis. 
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Two main types of genetic instability (essential condition for tumors to develop and progress 
towards more malignant stages) have also been recognized in human CRC, they consist in 
microsatellite instability (MSI) and chromosomal instability (CIN) [49]. MSI results from loss of 
mismatch repair (MMR) function and is earmarked by tumor-specific frame-shift mutations in 
stretches of short repetitive DNA sequences (microsatellite repeats) distributed throughout the 
genome [50, 51]. Somatic defects in the same MMR genes well known in the autosomal dominant 
predisposition to CRC, HNPCC, are also found in approximately 15% of sporadic colon cancers. 
The vast majority of CRCs are characterized by abnormal chromosomal contents with a 
heterogeneous and broad spectrum of both numerical and structural changes such as inversions, 
deletions, duplications and translocations [52]. CIN, instead, may provide additional growth 
advantage to the cancer cell by accelerating the rate of LOH at tumor suppressor loci and/or by 
amplifying chromosomal regions encompassing oncogenes. Over 90% of all CRCs show 
chromosomal aberrations, some of which are recurrent and represent key chromosomal changes 
underlying colorectal cancer initiation and progression. 
Also, epigenetic alterations such as DNA methylation and histone acetylation play an essential role 
in CRC progression. In fact, DNA methylation and thus inactivation of suppressor genes such as 
MLH1, p14 (upstream inducer of the p53 tumor suppressor pathway) and p16 occur in 
approximately 25-35% of colorectal cancers [53, 54]. Histone deacetylases (HDACs) instead are 
crucial regulating enzymes of histone acetylation, a phenomenon that is generally associated with 
transcriptional activation. Increased expression of HDACs in CRC has been demonstrated from 
several studies [55, 56] suggesting a physiological role in maintaining cell proliferation, survival 
and inhibiting differentiation.  
The identification of stepwise acquisition of specific mutations in colorectal cancer has provided 
important clues relative to the cellular processes underlying tumorigenesis in the gastro-intestinal 
tract and has opened new avenues for tailor-made therapeutic approaches. 
 
 
1.2.3 Colorectal cancer staging 
 
Colorectal cancer staging is related to the depth of tumor penetration into the bowel wall and the 
presence of both regional lymph node involvement and distant metastases. These variables are 
incorporated into the staging system introduced by Dukes [57] and applied to a TNM classification 
method [American Joint Committee on Cancer (AJCC)], in which T represents the depth of tumor 
penetration, N the presence of lymph node involvement, and M the presence or absence of distant 
metastases (Figure 1.2.3). Superficial lesions that do not involve regional lymph nodes and do not 
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penetrate through the submucosa (T1) or the muscularis (T2) are designated as stage I (T1–2N0M0) 
disease; tumors that penetrate through the muscularis but have not spread to lymph nodes are stage 
II disease (T3N0M0); regional lymph node involvement defines stage III (TxN1M0) disease; and 
metastatic spread to sites such as liver, lung, or bone indicates stage IV (TxNxM1) disease. It results 
clear that a proper staging of CRC is important for subsequent therapeutic assessment.  
 
 
Figure 1.2.3: Staging of colorectal cancer. Figure has been reproduced from [58] 
 
 
 
1.2.4 CRC treatment 
 
Colorectal cancer therapy approach is closely related to the stage of the disease. Presently, the main 
therapy approaches for patients with CRC are surgery, radiation therapy, chemotherapy and targeted 
therapies (e.g. monoclonal antibodies). Depending on the stage of cancer, two or more of these 
types of treatment may be combined at the same time or used after one another. 
Surgical resection remains the cornerstone of curative management of colorectal cancer [59], while 
radiation therapy is most effective as additional or adjuvant therapy either before or after surgery as 
it is shown to reduce the chance of cancer spread or recurrence [60]. Chemotherapy instead, 
represents the basis of metastatic CRC (mCRC) patients' therapy as approximately 50% of the 
patients with CRC develop metastases, and most probably die for the disease [61].  
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The goals of chemiotherapy of mCRC include palliation of symptoms, prolongation of life, and, in 
selected cases of liver-only metastases, tumor regression to facilitate surgical resection of these 
metastases. Thanks to multiagent systemic therapy the median survival of a patient who has mCRC 
has improved during the last decade from less than 6 months to approximately 2 years [62, 63, 64]. 
5-FU, often modified by leucovorin (LV), has been clinically used for half a century [65] as a 
standard agent for mCRC. It was the only available agent until 1996, when irinotecan was 
approved. Over the last decade, oxaliplatin, capecitabine, bevacizumab, cetuximab, and most 
recently panitumumab have also been approved by the US Food and Drug Administration (FDA).  
5-FU is inactive in its parent form and is converted within the cell to the cytotoxic metabolite 
fluorodeoxyuridine monophosphate (FdUMP). FdUMP forms a ternary complex with the reduced 
folate 5,10-methylenetetrahydrofolate and the enzyme thymidylate synthase (TS), which then leads 
to TS enzyme inhibition and subsequent inhibition of DNA synthesis and DNA repair. 5-FU can 
also be falsely incorporated into RNA and DNA, which leads to inhibition of mRNA translation and 
protein synthesis as well as inhibition of DNA synthesis and function, respectively. 
LV (folinic acid) administration increases the intracellular pool of key reduced folates, specifically 
5,10-methylenetetrahydrofolate, and stabilizes FdUMP and TS in a ternary complex and leads to 
optimal inhibition of the TS enzyme. To date, LV has been the most successful biomodulatory 
agent to be combined with 5-FU. 
Capecitabine is an oral fluoropyrimidine with a similar mechanism of action and similar efficacy as    
5-FU. Irinotecan is a derivative of camptothecin, found in Camptotheca acuminate (plant native to 
China) that inhibits DNA topoisomerase I and induces single-strand DNA breaks and replication 
arrest. Oxaliplatin is a third-generation platinum analogue that inhibits DNA replication and 
transcription by forming inter- and intra-strand DNA adducts/cross-links and induces apoptotic cell 
death. 
Both LV (FOL, folinic acid) and 5-FU (F, fluorouracil) can be combined with irinotecan (IRI) or 
oxaliplatin (OX) with the treatment acronyms FOLFIRI or FOLFOX, respectively. These 
alternative treatments consist of administration of a bolus of 5-FU, LV, and either oxaliplatin or 
irinotecan and are shown to have similar efficacy [66, 67]. Either FOLFOX or FOLFIRI are 
therefore considered standard options for first-line treatment of mCRC. These regimens are 
typically given with bevacizumab, witch is an example of target therapy together with cetuximab 
and panitumumab. Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth 
factor (VEGF) ligand to inhibit angiogenesis. Its antineoplastic effect is ascribed to regression of 
microvascular density, inhibition of neovascularization, and normalization of grossly abnormal 
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tumor vasculature that permits more effective chemotherapy delivery to the tumor thus improving 
progression-free survival for mCRC patients [68]. 
Cetuximab and panitumumab therapy target, in mCRC treatment, is represented by EGFR (for 
details on EGFR and its role in cancer see Chapters 1.3 and 1.4). Both drugs are monoclonal 
antibodies (respectively chimeric human/mouse and fully humanised) able to inhibit ligand binding 
to the receptor and have been approved from FDA for the treatment of mCRC that has progressed 
on or following 5-FU, oxaliplatin, and irinotecan-containing regimens [69, 70, 71].  
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1.3 EPIDERMIAL GROWTH FACTOR RECEPTOR  
 
The epidermal growth factor receptor (EGFR/Her1/ErbB1) is a type I transmembrane receptor 
tyrosine kinase and a member of the ErbB receptor family. This family includes three other 
members: ErbB2 (Her2/Neu), ErbB3 (Her3), and ErbB4 (Her4). The 11 ligands currently identified 
for these receptors include epidermal growth factor (EGF), transforming growth factor alpha    
(TGF-α), HB-EGF (heparin binding EGF), betacellulin (BTC), amphiregulin (AR), epiregulin 
(EPR), epigen and the neuregulins (NRGs) 1-4 [72]. The exception is ErbB2 for which no natural 
ligand has yet been discovered.  
 
                                                     
 
Figure 1.3: Epidermal growth factor family of ligands and the ErbB family. The inactive ligand-binding domains of 
ErbB2 and the inactive kinase domain of ErbB3 are denoted with an X. 
 
 
On ligand binding, EGFR can either undergo receptor dimerization by binding to a second EGFR 
molecule or preferentially form a heterodimer with other members of the ErbB family, with the 
greatest affinity to ErbB2 [73]. However, it does not appear that ErB2 homodimerizes at 
physiological expression levels, and homodimerization of ErbB3 receptors would not lead to 
receptor phosphorylation since ErbB3 is kinase inactive and thus must be trans-activated by 
heterodimerization with other ErbB receptors. The receptor dimerization subsequently mediates the 
activation of a complex signaling network that regulates cell growth, proliferation, survival, 
invasion and migration, and even angiogenesis [74].  
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1.3.1 Biochemical and structural characterisation of EGFR 
 
EGFR is a 170 kDa protein that is heavily N-glycosylated [75], with carbohydrate accounting for 
~20% of the molecular mass. The EGFR extracellular region is divided into four domains, 
numbered I-IV (Figure 1.3.1-1). Domains I and III (DI and DIII), also designated L1 and L2, are 
members of the leucine rich repeat family and are similar to domains found in the insulin receptor 
family [76]. Prior to receptor crystallization, it was known that both DI and DIII contribute to ligand 
binding [77]. Domains II and IV (DII and DIV), or the cysteine-rich (CR) domains, contain multiple 
small disulfide-bonded modules similar to those in laminin [78]. 
 
 
 
 
Figure 1.3.1-1: Schematic representation of EGFR domains. The extracellular region consists of domains I-IV, 
followed by a transmembrane region (TM) and the intracellular portion including the juxtamembrane domain (JM), the 
tyrosine kinase domain (TK), and the C-terminal tail containing tyrosine residues which become phosphorylated upon 
receptor activation. 
 
 
 
The EGFR ectodomain has been crystallized in both monomer and dimer forms. The monomer 
exists in a tethered, closed, or autoinhibited state [79], with DII and DIV forming a tether contact              
(Figure 1.3.1-2, left). However, in the dimer structures of EGFR bound to EGF [80] or TGF-α [81], 
the receptor is in an untethered, open, or extended conformation, with ligand binding between DI 
and DIII (Figure 1.3.1-2, right). Although most cytokine receptors dimerize through ligand bridging 
the two receptor monomers [82], all dimerization contacts in the EGFR dimer are fully        
receptor-mediated. The dimer exists in a 2:2 receptor to ligand ratio, with multiple contacts through 
the DII dimerization arm (residues 242-259). An additional DII loop, residues 271-283, also 
contributes to important dimer contacts [83]. The dimerization interface may include DIV; however, 
in the dimer structures, DIV is either unresolved [80] or was not present in the crystallized protein 
[81]. Peptides mimicking portions of DIV can inhibit EGFR heterodimerization with Her3 [84], and 
 19 
DIV mutations can impair the ability of ligand to bind and induce EGFR phosphorylation [85]. 
However, these potential DIV contacts contribute <9% of the free energy of dimerization as 
demonstrated by studies on soluble EGFR dimer formation [83]. For illustrative purposes, DIV has 
been added to the dimer structure in Figure 1.3.1-2 in the same relative orientation to DIII as seen in 
the tethered monomer. A low-resolution molecular envelope structure of the full EGFR dimer in 
solution has been obtained from small-angle X-ray scattering (SAXS), and it is consistent with this 
dimer structure [86]. 
 
 
 
Figure 1.3.1-2: Crystal structures of monomeric and dimeric EGFR. Left) autoinhibited EGFR monomer, with domain I 
(DI), red; DII, orange; DIII, blue; DIV, green. A 130° rotation of DI and DII allows DI and DIII to come together to 
bind EGF ligand. Right) dimeric EGFR bound to EGF ligand in yellow. DIV is not resolved in this structure, but has 
been added in the same relative orientation to DIII as seen in the monomer. Figure has been reproduced from [87]. 
 
 
 
From the crystal structures of the monomer and dimer, a model for EGFR activation has been 
proposed [87]. In this model, the monomer mostly exists in a tethered conformation, in which the 
DII dimerization arm and other residues are obscured, thus preventing receptor dimerization. The 
monomer equilibrates between the tethered conformation and an extended conformation similar to 
that seen in the dimer. The binding of ligand between DI and DIII stabilizes the extended 
conformation, which exposes the DII dimerization arm and other residues, thus allowing the 
formation of the dimer. However, the breaking of the tether is necessary but not sufficient for dimer 
formation, as demonstrated through mutations and deletions of DIV [81, 88, 89]. It also appears that 
certain types of receptor glycosylation can shift the equilibrium toward the extended form [90, 91]. 
It has subsequently been found that the DII-DIV tether interaction is not necessarily responsible for 
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maintaining the receptor in the autoinhibited conformation; in fact, mutating every tether interaction 
in soluble EGFR still leads to an autoinhibited conformation [86]. In addition, it appears that ligand 
binding is necessary to stabilize the conformation of the DII loop 271-283, which is an important 
dimerization contact [83].  
EGFR has a single transmembrane domain, and the intracellular portion contains a short 
juxtamembrane region, the tyrosine kinase, and a C-terminal tail containing tyrosine residues which 
become phosphorylated upon receptor activation (Figure 1.3.1). The EGFR kinase domain has been 
independently crystallized, revealing an intrinsically autoinhibited domain resembling Src and     
cyclin-dependent kinases (CDKs) [92]. In contrast to most kinases, phosphorylation of the EGFR 
activation loop is not necessary for its activation [93]. Instead, the EGFR kinase is activated by an 
asymmetric dimer in which the C-terminal lobe of one kinase domain binds to the second kinase 
domain in a manner analogous to cyclin in activated CDK/cyclin complexes. Thus, ligand binding 
brings two receptor monomers together and allows for the dimerization and subsequent activation 
of the kinase domains. The extent of EGFR kinase activation depends on the effective local 
concentration of the receptor, since the probability of dimerization will increase with increasing 
kinase domain density as experimentally demonstrated using increasing concentrations of EGFR 
kinase domains tethered to the vesicles surface [92].   
 
 
1.3.2 EGFR: Signaling and trafficking 
 
The receptor dimerization event allows for kinase activation and trans-phosphorylation of residues 
in the intracellular domain of EGFR. The phosphorylated tyrosine residues and the surrounding 
amino acids are specifically tailored to interact with a unique collection of second messengers such 
that, depending on the stimulating ligand and dimerization partner, a specific biological response 
may be precisely induced [72]. Following stimulation of EGFR by EGF, the major sites of 
phosphorylation include tyrosines 1068, 1148, 1173 [94]. These phosphorylated tyrosines serve as 
specific binding sites for several adaptor proteins, such as phospholipase Cγ, CBL, GRB2, SHC and 
p85, mainly characterized by the presence of the phosphotyrosine binding domain (PTB), SH3 
domains that recognize proline-rich sequences and SH2 domains (Src-homology 2). Many of these 
interactions have been characterized in detail, such as GRB2 binding to EGFR tyrosine 1068 and 
SHC binding to EGFR tyrosines 1148 and 1173 [95, 96]. Several signal transducers then bind to 
these adaptors to initiate multiple signaling pathways, including mitogen-activated protein kinase 
(MAPK), phosphatidylinositol 3-kinase (PI3K) ⁄AKT and the signal transducer and activator of 
transcription (STAT) pathways [97]. 
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As mentioned earlier, KRAS protein is a pivotal downstream component of the EGFR signaling 
cascade able to activate the Ras/Raf/MEK/ERK pathway, which mediates cell growth and cell cycle 
entry via phosphorylation of key transcription factors (c-FOS and MYC) of target genes like        
Cyclin-dependent kinases and Cyclins [17]. The PI3K signaling cascade, instead, plays an integral 
role in regulating several key cellular processes including cell survival and growth, proliferation, 
cell migration and angiogenesis [98]. The most relevant effector of PI3K for cell proliferation and 
survival is the serine/threonine kinase Akt. Activation of Akt leads to enhanced cell growth and 
proliferation through downregulation of p21 and p27 cell cycle inhibitors, through increased 
translation and stabilization of cyclin D1, while the process of cell survival is mediated through 
several different mechanisms, including inhibition of the pro-apoptotic Bcl-2 family member Bad 
[99]. The third EGFR downstream pathway is represented by STAT proteins, latent cytoplasmic 
transcription factors able to convey signals from growth-factor receptors to the nucleus. Homo- and 
heterodimerization of STAT proteins is a prerequisite for activation and translocation to the 
nucleus, and is mediated by tyrosine phosphorylation of critical residues. EGFR activation results in 
STAT dimers activation that play a crucial role in fundamental biological processes such as cell 
proliferation, apoptosis and angiogenesis, thus finding place in a pivotal position for tumorigenesis 
[100]. It is important to note that STAT regulation of genes that control cell proliferation and 
survival varies among different tumour types [101,102] due to cell-type specific differences in 
STAT-interacting proteins, such as other transcription factors [103, 104]. 
In addition, EGFR can be trans-activated by other proteins, such as G-protein-coupled receptors 
(GPCRs) [105]. The various signaling cascades associated with EGFR activation are summarized in 
Figure 1.3.2-1. It has also been observed that activated EGFR may undergo nuclear 
translocalization and subsequently regulate gene expression: in fact chromatin immunoprecipitation 
studies demonstrated that EGFR is associated with the promoter region of cyclin D1 gene [106]. 
The activation of EGFR thus leads to multiple cell responses, including cellular growth, 
differentiation, and migration. 
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Figure 1.3.2-1: EGFR signaling network. a) EGFR family ligands are shown with their binding specificities, other 
ligand specificities are shown in parentheses. b) Signaling to the adaptor protein/kinase layer. c) Possible cellular 
outcomes based on EGFR signaling. Figure has been reproduced from [106]. 
 
 
 
In the absence of ligand, EGFR is constitutively internalized with a half life of ~30 minutes and 
quickly recycled back to the cell surface, leading to a total receptor distribution of ~80-90% on the 
cell surface at any given time (Figure 1.3.2-2) [107]. The metabolic half-life of EGFR in a tumor 
cell line is          20 hours [108]; thus, a single receptor will cycle through the endocytic pathway 
many times during its lifetime. Ligand activation increases the rate of EGFR endocytosis 5-10 fold 
[109]. In addition, activated EGFR dimers bound to EGF are preferentially retained in the 
endosomes and not recycled [110], and these endosomes mature into multivesicular bodies and are 
targeted to lysosomes [111]. This leads to the specific degradation of activated receptors and overall 
receptor downregulation. Earlier reports indicated that ligand-accelerated internalization required 
EGFR kinase activity [112, 113], but a recent study found that receptor dimerization was sufficient 
to induce rapid internalization and that kinase activity was unnecessary [114]. Although receptor 
ubiquitination does not affect EGFR internalization rates [115, 116], ubiquitination by c-Cbl targets 
receptors to the lysosome and is dependent on kinase activity and an intact C-terminal region [117]. 
While receptor internalization has often been viewed as a means of signaling attenuation, it has 
been shown that activated EGFR continues to signal while in the endosome through certain 
signaling pathways [118, 119]. Mathematical modelling and experiments have also demonstrated 
that ErbB2, often described as the preferred heterodimerization partner for ErbB receptors [73], 
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reduces the rate of internalization and increases the fraction of recycled EGFR/Her2 heterodimers 
[120]. 
For its importance EGFR trafficking has been the subject of much mathematical modelling, and the 
system serves as a paradigm for other ligand-binding receptors [108, 121, 122]. 
 
 
 
 
Figure 1.3.2-2: EGFR intracellular trafficking. Activated EGFR homo- and heterodimers are internalized through 
clathrin-coated pits and preferentially degraded. Approximate mean time of the processes are indicated. Figure has been 
reproduced from [108]. 
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1.4 EGFR ROLE IN CANCER 
 
EGFR was the first receptor to be directly linked to human cancer [123], and because EGFR 
activation often leads to cellular growth, its signaling can provide tumor cells with substantial 
survival advantages. In addition, EGFR signaling has been implicated in tumor cell production of                        
pro-angiogenic factors and cellular migration and invasion [124]. In fact, upstream of RAS, 
activation of EGF receptor has been shown to induce scattering of human cancer cells via tyrosine 
phosphorylation of β-catenin [125]. In particular, β-catenin tyrosine phosphorylation at residue 654 
results in loss of cell-cell adhesion by disturbing the functionality of the adherens junction 
functionality through E-cadherin destabilization and loss of contact with the actin cytoskeleton 
[126]. These effects on cell-cell adhesion underlie epithelial to mesenchymal transitions (EMT) and 
are known to contribute to local invasion and distant cancer metastasis. EGFR dysregulation has 
been observed in a wide variety of carcinomas, including colorectal, head and neck, breast, bladder, 
and non-small-cell lung cancer (NSCLC) [105]. Excessive EGFR signaling can arise from receptor 
overexpression, autocrine signaling, or mutation. Normal cells usually express 4x104 to 1x105 EGF 
receptors per cell, but tumor cells can express as many as 2x106 [127]. Receptor overexpression 
commonly develops due to gene amplification, although it was quite recently reported that the 
hypoxic microenvironment of tumors can also induce overexpression of EGFR by increasing EGFR 
mRNA translation [128]. In CRC, 22-75% of tumors overexpress EGFR [129], and the observed 
percentages of tumors overexpressing EGFR in various types of cancer are listed in Table 1.4. 
Furthermore, elevated levels of EGFR serve as a prognostic indicator for poor survival rates [130].  
 
 
 
Table 1.4: EGFR overexpression in different tumor types. 
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In addition, EGFR ligands can be overexpressed, resulting in high levels of autocrine signaling 
when the receptor is present [131]. Autocrine production of TGF-α or EGF is also associated with 
reduced cancer survival [132]. Various activating EGFR mutations have been observed in tumor 
samples. Mutations in the EGFR kinase domain, which are clustered around the ATP-binding 
pocket of the enzyme, have been observed in many types of carcinomas including ovarian, 
colorectal, and head and neck and NSCLC. Most of these mutations have been shown to 
hyperactivate the kinase and have oncogenic activity [133]. 
Finally, in addition to the full-length transmembrane forms of ErbB receptors, normal and 
malignant cells synthesize soluble ErbB isoforms (sErbBs) that lack the TMD and ICD of the 
receptor, as well as proteolytically truncated isoforms (tErbBs) that encompass only the TMD 
and/or ICD of the receptor [reviewed by 134] (Figure 1.4.1). Soluble ErbB isoforms have been 
identified for all four members of the ErbB family and can be generated either by alternate mRNA 
splicing/processing events or via proteolytic cleavage of the full-length receptor. This events result 
in 60-kDa, 80-kDa and 110-kDa sErbB1/sEGFR isoforms; 68-kDa, 100-kDa, 105-kDa and         
110-kDa sErbB2 isoforms; 20-kDa, 45-kDa, 50-kDa, 76-kDa, and 85-kDa sErbB3 isoforms; and 
the 120-kDa isoform of sErbB4 (Figure 1.4.1) [134]. The natural occurrence of this soluble, 
truncated, and other alternate ErbB receptor isoforms produces yet another level of complexity on 
the regulation of EGFR signal transduction. 
 
 
 
 
Figure 1.4.1: Schematic summary of full-length, soluble, truncated, and alternate human ErbB receptors. Gray boxes) sErbBs 
produced by proteolytic cleavage, dotted boxes) sErbBs produced by alternate transcripts, cross-hatched boxes) the only 
known “sErbB” resulting from an aberrant translocation event involving the EGFR gene. Figure has been reproduced from 
[134]. 
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Because of the importance of EGFR family in cancer and in particular in CRC, EGFR is a 
promising target for rational oncology therapies designed to inhibit receptor signaling. Targeting the 
ErbB network may be achieved by inhibiting the tyrosine kinase (catalytic domain) with small 
molecules (TKIs) or by inhibiting the extracellular domain with monoclonal antibodies (Figure 
1.4.2). 
 
 
 
 
Figure 1.4.2: EGFR network and target therapies. 
 
 
Gefitinib (Iressa, ZD1839; AstraZeneca) [135] and erlotinib (Tarceva, OSI-774; 
OSI/Genentech/Roche) [136] are two EGFR-targeted TKIs approved from the FDA for the 
treatment of mCRC, that inhibit receptor autophosphorylation and block downstream signal 
transduction. As previously described, monoclonal antibodies such as cetuximab (Erbitux,        
IMC-C225; ImClone Systems) and panitumumab (Vectibix, ABX-EGF; Amgen/Abgenix) block the 
interaction between natural ligands and the EGF receptor in the extracellular space resulting in 
decreased tyrosine phosphorylation and reduced cell proliferation as well as increased rate of 
receptor internalization. Despite their promising effects in CRC, the forementioned EGFR target 
therapies have shown little activity, due to the established resistance mechanisms [137, 138], and 
elevated adverse events including diarrhoea, skin toxicity (including acne-like rash), neutropenia 
and asthenia that have been largely reported [61, 139]. 
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1.5 AIM OF THE RESEARCH 
 
EGFR abnormalities are associated with all aspects of carcinogenesis, cell proliferation, inhibition 
of apoptosis, angiogenesis and metastasis. Overexpression of EGFR has been reported in several 
tumor types, most notably colorectal (object of this study), head and neck, and lung cancers, where 
it typically correlates with poor clinical outcomes. Thus, interference with EGFR receptor activation 
and/or with its intracellular signal transduction pathways represents a promising strategy for the 
development of novel and selective anticancer therapies. To date, two strategies for therapeutic 
inhibition of EGFR are under clinical development for the treatment of CRC: monoclonal 
antibodies and TKIs. Although results seemed to be encouraging they have shown little activity, due 
to the established resistance mechanisms, and elevated cytotoxicity.  
In this respect, shikonin is a naturally occurring naphtoquinone isolated from the roots of many 
traditional medicinal plants, that has been demonstrated to have great anti-tumor potential by 
inhibiting the cell growth of various cancer cell lines, inducing apoptosis in leukemia HL-60 cells 
and inhibiting EGFR signaling in human epidermoid carcinoma cells [140, 141]. Moreover, a 
shikonin derivative, β-hydroxyisovalerylshikonin, strongly inhibits EGFR kinase activity and 
inhibition results non-competitive with respect to ATP, suggesting that both it and the parent 
compound may bind to the peptide-binding site [142, 143]. 
In this thesis work, the anti-tumor activity and the efficacy of FR18, 2-(8-amino-octylamino)-
[1,4]naphthoquinone, a molecule containing the same naphtoquinone core as shikonin, was tested as 
a novel EGFR inhibitor by using the human colon adenocarcinoma cell line, HT-29, as a cellular 
model. Flow cytometry, immunoprecipitation, western blot and confocal spectral microscopy 
analysis were performed in order to evaluate the biological effects induced by FR18 on HT29 cells, 
paying particular attention to the tyrosine kinase activity and to the ability of the epidermial growth 
factor receptor to bind its natural ligand, EGF. 
Therefore, a second aspect of the research was focused on the investigation of the direct EGF/EGFR 
complex interaction which represents a challenging but important system that can lead to significant 
general knowledge about receptor-ligand interactions, and the design of new drugs intended to 
interfere with EGFR binding activity. EGF/EGFR interaction studies were performed by surface 
plasmon resonance (SPR) biosensor technique which allows the study of biomolecular interactions 
in real-time and label-free with a high degree of sensitivity and specificity.  
 
 
 
 
 
 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. TECHNIQUES 
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2.1 CONFOCAL LASER SCANNING MICROSCOPY  
 
Laser scanning confocal microscopy (LSCM) is an invaluable tool for a wide range of 
investigations in the biological and medical science primarily because the technique enables 
visualization deep within both living and fixed cells and tissues and affords the ability to collect 
sharply defined optical sections from which three-dimensional renderings can be created. 
The basic concept of confocal microscopy was originally developed by Marvin Minsky in the    
mid-1950s [144, 145]. During the late 1970s and the 1980s, advances in computer and laser 
technology, coupled to the application of a wide array of new synthetic and naturally occurring 
fluorochromes, led to a growing interest in confocal microscopy.  
In epi-illumination scanning confocal microscopy systems, the laser light source and 
photomultiplier detectors are both separated from the specimen by the objective, which functions as 
a well-corrected condenser and objective combination. Light emitted by the laser system (excitation 
source) passes through a pinhole aperture that is situated in a conjugate plane (confocal) with a 
scanning point on the specimen and a second pinhole aperture positioned in front of the detector    
(a photomultiplier tube) as shown in Figure 2.1.1. 
 
 
Figure 2.1.1: Optical pathway and principal components in an epi-illumination laser scanning confocal microscope. 
 
 30 
As the laser is reflected by a dichromatic mirror and scanned across the specimen in a defined focal 
plane, secondary fluorescence emitted from points on the specimen (in the same focal plane) passes 
back through the dichromatic mirror and is focused as a confocal point at the detector pinhole 
aperture.  
This optical configuration enables the following advantages: i) reduced image blur by scattered 
light, ii) increased resolution iii) improved signal-to-noise ratio, iv) the opportunity to cleary 
examine specimens in 3D. 
In traditional wide-field epi-fluorescence microscopy, the entire specimen is subjected to intense 
illumination from an incoherent mercury or xenon arc-discharge lamp, and the resulting image of 
secondary fluorescence emission can be viewed directly in the eyepieces or projected onto the 
surface of an electronic array detector.  
In contrast to this simple concept, the mechanism of image formation in a confocal microscope is 
fundamentally different. The significant amount of fluorescence emission that occurs at points 
above and below the objective focal plane and is not confocal with the pinhole is not detected by the 
photomultiplier and does not contribute to the resulting image. Refocusing the objective in a 
confocal microscope shifts the excitation and emission points on a specimen to a new plane that 
becomes confocal with the pinhole apertures of the light source and detector.  The result is a set of 
optical sections that collected and summed along the z axis allows the reconstruction of specimen’s 
3D structure. Resolution along the z axis for a confocal microscope is given by: 
zmin = 2λη/(ΝΑ2)    
where η is the medium refraction index, λ the wavelength and N.A. is the numerical aperture. 
The confocal image of a specimen is reconstructed, point by point, from emission photon signals by 
the photomultiplier and accompanying electronics, yet never exists as a real image that can be 
observed through the microscope eyepieces. 
BioRad MRC1024 UV and Nikon C1s confocal laser scanning microscopes were used in this thesis. 
BioRad MRC1024 UV system uses a two laser exitation: i) Argon ion UV laser (Coherent), 
emitting at 357 nm, 361 nm and 488 nm, powered with 100 mW, ii) Krypton/Argon ion visible 
laser (Bio-Rad), which emits at wavelengths of 488 nm, 568 nm and 647 nm and is powered with 
15 mW. The two lasers are coupled to scan head through an optical fibre connection. The scan head 
(Figure 2.1.2) contains, in addition to the fluorescent filter sets, three photomultiplier tubes. The 
scanning is done by a galvanometer-based raster scanning mirror system.  
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Figure 2.1.2: Diagram of the scanning head in Bio-Rad 1024 UV. Laser light (Ex) reflected by dichromatic mirror (BS) 
is sent to the objective (Ob) through the M1 mirror, the G1 and G2 galvanometric mirrors and the CM1 and CM2 
convex mirrors. Emitted fluorescence is sent to the photomultiplier (PMT) through the M2, M3 and M4 mirrors system. 
 
 
The microscope used is the Nikon Eclipse TE300: an inverted microscope equipped for 
conventional light microscopy, fluorescence, reflection and phase contrast. Windows NT operating 
system is used together with LaserSharp 2000 acquisition software (Bio-Rad, Hercules, CA). 
Nikon C1s instrument permits the acquisition of spectral imaging (also referred to as emission 
fingerprinting) followed by linear unmixing of emission profiles in specimens labeled with 
combinations of fluorescent proteins or fluorophores having overlapping spectra. 
Nikon C1s uses a three laser exitation: i) BD laser, emitting at 405 nm, powered with 25 mW,       
ii) Argon ion laser, which emits at wavelengths of 488 nm and is powered with 10 mW, iii) R-HeNe 
laser emitting at 633 nm powered with 5mW. The lasers unit is coupled to the scan head through an 
optical fibre connection. As shown in Figure 2.1.3, the scanning head is coupled to a standard 
fluorescence detector which permits simultaneous 3-channel fluorescence imaging and a spectral 
detector able to acquire 32 channels of fluorescence spectra over a 400-750 nm wavelength range 
with a switchable wavelength resolution of 2.5 nm, 5 nm, or 10 nm. 
Nikon Eclipse TE300 UV confocal microscope, equipped with a Nikon PlanApo 60×, 1.4-NA oil 
immersion lens is used and images are analyzed using the EZ-C1 software (Nikon). 
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Figure 2.1.3: Schematic representation of Nikon C1s spectral imaging confocal laser microscope. 
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2.2 SURFACE PLASMON RESONANCE BIOSENSORS (BIACORE) 
 
Biosensors are analytical devices comprised of a biological element (tissue, microorganism, 
organelle, cell receptor, enzyme, antibody) and a physico-chemical transducer. Specific interaction 
between the target analyte and the biological material produces a physico-chemical change detected 
by the transducer. The transducer then yields an analogical electronic signal proportional to the 
amount (concentration) of a specific analyte or group of analytes. 
 
Surface Plasmon Resonance (SPR) biosensor technology is a label-free technology for monitoring 
biomolecular interactions as they occur [146]. The detection principle relies on SPR, an electron 
charge density wave phenomenon that arises at the surface of a metallic film when light is reflected 
at the film under specific conditions. The resonance is a result of energy being transformed from 
incident photons into surface plasmons, and is sensitive to the refractive index of the medium on the 
opposite side of the film from the reflected light. 
When incident polarised light is passed through a higher refractive index material (glass) to a lower 
refractive index material (air), part of the light is reflected and part is refracted. When the angle of 
incident light is greater than a critical angle, total internal reflection occurs (TIR) and the electric 
field component of the light, also called evanescent wave, propagates and decays exponentially 
along the interface of the two media. If the TIR interface is coated with a noble metal (gold) film 
the photon energy of the evanescent wave is transferred to the free electrons within the gold film 
(plasmons) which excited give rise to an additional electric field. At a defined angle of incidence 
(resonance angle) the wave vectors of the plasmons and the evanescent field are coupled and 
surface plasmon resonance occurs. This resonance can be physically observed by the sudden drop in 
angle-dependent reflectance accompanied by energy loss (Figure 2.2.1). This is called the minimum 
of reflectance and is the typical data point recorded in experimentation. SPR-dip shift in time is 
measured in resonance units (RU).  
 
                                             
Figure 2.2.1: SPR is observed as a dip in the reflected light intensity at a specific angle of reflection. 
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Biacore (GE Healthcare, Uppsala, Sweden) has pioneered commercial SPR biosensors offering a 
unique technology for collecting high quality, information-rich data from biomolecular binding 
events. Biacore’s optical biosensors (Figure 2.2.2) are designed around three core technologies: 
 
1. An optical detector system that monitors the changes in SPR signal brought about by binding 
events in real time. 
2. An exchangeable sensor chip consisting of a glass slide and a thin gold-film upon which one 
of the interacting biomolecules is immobilized or captured. The resulting biospecific surface is 
the site where biomolecular interactions occur.  
3. A microfluidic and liquid handling system that precisely controls the flow of buffer and 
sample over the sensor surface. 
 
These systems are contained within the processing unit that communicates with a computer 
equipped with control and data evaluation software.  
 
 
 
 
Figure 2.2.2: Schematic representation of SPR biosensors. 
 
 
In the simplest case of an SPR measurement, a target component or analyte is captured by the 
capturing element or so-called ligand. The ligand is permanently immobilized on the sensor surface 
previous to the measurement. Molecules can be covalently linked to sensorchips with several 
binding techniques utilizing different intrinsic active groups in the ligands. 
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The most common coupling chemistries are showed in Figure 2.2.3. 
Figure 2.2.3: Common coupling chemistries applied to immobilize molecules on Biacore sensor chips. 
 
 
The event of capturing the analyte by the ligand gives rise to a measurable signal called direct 
detection. Figure 2.2.4 shows the sensor signal step-by-step in the measurement cycle with direct 
detection.  
 
 
 
 
Figure 2.2.4: Sensorgram showing the steps of an analysis cycle: 1. the buffer is in contact with the sensor (baseline);   
2. continuous injection of sample solution (association); 3. buffer injection (dissociation step); ∆R indicates the 
measured response due to the bound target compound; 4. removal of bound species from the surface during injection of 
regeneration solution (regeneration step) followed by a new analysis cycle. A bulk refractive index shift can be 
observed at t1. 
RU 
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Each measurement starts with conditioning the sensor surface with a suitable buffer solution (1). It 
is of vital relevance to have a reliable baseline before the capturing event starts. At this point, the 
sensor surface contains the active ligands, ready to capture the target analytes. On injecting the 
solution containing the analytes (2), they are captured on the surface. Also other components of the 
sample might adhere to the sensor surface; without a suitable selection of the ligand, this adherence 
will be non-specific, and thus easy to break. At this step, adsorption kinetics of the analyte molecule 
can be determined in a real-time measurement. Next, buffer is injected on to the sensor and the    
non-specifically bound components are flushed off (3). As indicated in the figure, the accumulated 
mass can be obtained from the SPR response (∆R). Also in this step, dissociation of the analyte 
starts, enabling the kinetics of the dissociation process to be studied. Finally, a regeneration solution 
is injected, which breaks the specific binding between analyte and ligand (4). If properly anchored 
to the sensor surface, the ligands remain on the sensor, whereas the target analytes are quantitatively 
removed. Again, buffer is injected to condition the surface for the next analysis cycle.  
Often SPR measurements are carried out to determine the kinetics of a binding process. Pseudo 
first-order kinetics are assumed, and the change in SPR angle is recorded as a function of time. 
Reaction rate constants of interactions can be determined, e.g. the interaction A+B=AB can be 
followed in real time where A is the analyte and B is the ligand immobilized on the sensor surface. 
Table 2.2 contains the most relevant kinetic parameters, the association and dissociation constants, 
for the simplest case A+B=AB.  
 
Table 2.2: Definitions of the most relevant kinetic parameters: association and dissociation constants. 
 
 
 
The association constant is the reaction rate of complex (AB) formation, giving the number of 
complexes formed per time at unit concentration of A and B. As soon as the complex AB is formed, 
its dissociation can start. The dissociation rate constant describing this process expresses the 
number of AB complexes dissociating per unit time. Association rate constants can be measured 
ranging from 103 to 108 M−1 sec−1 and dissociation rate constants from 10−5 to 1 sec−1 [147]. 
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BIAevaluation software's equipped with different kinetic models allow the calculation of affinity 
constants (KD = kassociation/kdissociation) from experimentally obtained association and dissociation rate 
constants. The typical working range for affinity measurements with Biacore’s biosensors is 
picomolar to high micromolar for KD (M).  
The biosensors used in this thesis were Biacore 2000 and Biacore S51.  
Biacore 2000 is currently the most widely used Biacore instrument. It is equipped with a robotic 
autosampler and can be programmed through the use of wizards or methods in the control software 
to automatically inject samples for up to two 96-well microtiter plates. The fluidic system in this 
instrument creates four serially linked flow cell areas on one sensor chip, thereby increasing the 
potential number of simultaneous measurements. For example, it is possible to simultaneously 
collect data from a reference surface as well as three other surfaces with different immobilized 
ligands as well as reference-subtracted data for each surface.  
Biacore S51, instead, offers a unique platform designed for screening applications and kinetic 
characterization of low-molecular weight compound leads. There are two independent flow cells in 
Biacore S51, each of which contains three detection spots. The central spot is used as a reference 
surface, while different molecules can be immobilized on the outer two spots using hydrodynamic 
addressing.  
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3. MATERIALS AND METHODS 
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3.1 CELL CULTURE AND TREATMENTS  
 
To study the effects of the administration of FR18 on colon carcinoma cells we used the HT-29 cell 
line (Zooprofilatic Institute of Brescia, Italy). The human epidermoid cell line, A431 (Zooprofilatic 
Institute of Brescia, Italy) was also used to perform surface plasmon resonance (SPR) studies. 
Both cell lines were propagated in monolayer cultures in RPMI 1640 (Euroclone, Milan, Italy) 
medium inoculated at a density of 104 cells/cm2. The medium was supplemented with 10% (v/v)                    
heat-inactivated (56°C for 20 min) fetal bovine serum (FBS) (Euroclone, Milan, Italy) and with      
2 mM L-glutamine (Sigma-Aldrich, St. Louis, MO). Cells were kept in an incubator at 37°C in 5% 
CO2 atmosphere and splitted every five-six days. Before splitting the cells were washed twice with 
phosphate buffer PBS, consisting of 8 g/L NaCl (Sigma-Aldrich, St. Louis, MO), 1.15 g/L Na2PO4             
(Sigma-Aldrich, St. Louis, MO), 0.20 g/L KH2PO4 (Sigma-Aldrich, St. Louis, MO), 0.20 g/L KCl 
(Sigma-Aldrich, St. Louis, MO), then detached with 0.11% Trypsin (Sigma-Aldrich, St. Louis, 
MO)/0.02% ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, St. Louis, MO) for 5  min at 
37°C. Detached cells were subsequently resuspended in fresh medium and counted in a Burker 
chamber. 
FR18, 2-(8-amino-octylamino)-[1,4]naphthoquinone, synthesized in the laboratory of Professor 
Melchiorre (Department of Pharmaceutical Sciences, University of Bologna, Italy), was dissolved 
in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) at a concentration of 10 mM and 
stored at +4°C as a stock solution. The drug was diluted in fresh medium before each experiment. 
EGF was purchased from Oncogene (Cambridge, MA), dissolved in 10 mM acetic acid at                
100 µg/ml, and stored at -20°C. Alexa Fluor® 488 EGF complex (Invitrogen, Carlsbad, CA), was 
dissolved in 200 µg/mL stock solutions in phosphate-buffered solution, containing 1% BSA with 
the addition of sodium azide at a final concentration of 2 mM, and stored at -20°C. EGF and 
fluorescent EGF were diluted in RPMI 1640 before each experiment at the indicated concentrations. 
Cells were serum starved according to experimental needs that is, cultured in RPMI 1640 medium 
supplemented with 0.25% FBS (v/v). 
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3.2 CELL PROLIFERATION ASSAY  
 
The cell growth inhibitory effect of FR18 on HT-29 cells was determined by using the                                 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, 
MO) assay [148].  
This assay is based on a colorimetric reaction, catalyzed by the mitochondrial succinic 
dehydrogenase enzyme, which converts the substrate (MTT) in a water insoluble formazan salt. The 
formation of this salt is a sign of cell integrity and therefore viability. HT-29 cells inoculated in     
96 multiwell plates at a density of 104 cells/cm2 after 24 hours of adhesion were treated in triplicate 
with increasing concentrations of FR18 in the range 10 nM-1.2 mM, for 24 hours. 
After treatment, cells were deprived of culture medium, spiked with 200 µL of a solution of MTT     
(0.2 mg/ml) in PBS and incubated for 2 hours at 37 ° C. The MTT solution was removed and the 
formazan salts solubilised in 200 µL of isopropanol (Sigma-Aldrich, St. Louis, MO) for 20 min in 
agitation at room temperature. The absorbance of the coloured solution was quantified at 570 nm 
using the Victor2 Wallac 1420 multilabel counter spectrophotometer.  
The IC50 value was calculated according to the GraphPad Prism 3.02 software relating the optical 
density at 570 nm with the logarithm of molar concentrations of FR18. 
 
 
 
3.3 CONFOCAL LASER SCANNING MICROSCOPY 
 
For confocal microscopy HT-29 were inoculated at a density of 104 cells/cm2 in 6 multiwell plates 
on borosilicate glass coverslips of  0.13 mm average thickness. 
After 24 hours of adhesion cells were serum starved for 48 hours and then treated for 30 min with   
5 µg of Alexa Fluor® 488 EGF complex  (Invitrogen, Carlsbad, CA), or both 2 µM FR18 and 5 µg 
of Alexa Fluor® 488 EGF complex. The reagents were both dissolved in serum-free fresh medium. 
For spectral imaging, preparations were washed with RPMI 1640, fixed with 3% paraformaldehyde, 
and embedded in mowiol (Hoechst, Frankfurt, Germany). Alexa Fluor® 488 was excited at 488 nm 
with an argon laser, and fluorescence was detected in spectral mode (Nikon C1s confocal          
laser-scanning microscope) in the interval 500-550 nm at 5 nm resolution. 
At least five cells were measured and the signal was corrected for background fluorescence by 
subtracting the average of the fluorescence detected from at least five extracellular regions from the 
same spectral image. 
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For EGF/EGFR complex confocal analysis, cells were treated with FR18 and Alexa Fluor® 488 
EGF complex, as described. The preparations were then washed twice in PBS, fixed with 3% 
paraformaldehyde (Sigma-Aldrich, St. Louis, MO) for 10 min at room temperature, washed thrice 
in 0,1 M glycine (Sigma-Aldrich, St. Louis, MO)  in PBS and permeabilized with 70% ice-cold 
ethanol for 2-3 min at -20°C. 
For indirect immunofluorescence, cells were left in agitation with 1% BSA in PBS for 60 min at 
room temperature and then incubated overnight at 4°C with the monoclonal primary antibody 
against EGFR (Biosource, Camarillo, CA) at a final concentration of 0.2 µg/mL in BSA/PBS. 
Subsequently the samples were washed twice with BSA/PBS and incubated for 1 h at room 
temperature with Alexa 568-conjugated secondary antibody 1:1,000 in BSA/PBS.  
Multiple images were acquired by using sequential laser excitations at 488 and 568 nm to reduce 
spectral bleedthrough artifacts. The images were collected by using a BioRad MRC1024 UV 
confocal microscope, equipped with a Nikon PlanApo 60X, 1.4-NA oil immersion lens, and 
analyzed by Image J (W.S. Rasband, ImageJ, NIH, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/, 
1997–2006). 
 
 
 
3.4 FLOW CYTOMETRY ANALYSIS 
 
Cells were treated for 24 h with FR18 (1 nM-5 µM) or 3 µg/mL anti-EGFR monoclonal antibody 
(Chemicon, Temecula, CA), detached by trypsinization, washed in PBS, and centrifuged at 240 g 
for 10 min. The pellet was resuspended in 0.01% Nonidet P-40 (Sigma-Aldrich, St. Louis, MO), 10 
µg/mL RNase (Sigma-Aldrich, St. Louis, MO), 0.1% sodium citrate, 50 µg/mL propidium iodide 
(PI)   (Sigma-Aldrich, St. Louis, MO) for 30 min at room temperature in the dark. The relationship 
between the quantity of cells to be analyzed and the volume of the solution was 106 cells /mL. 
 
Propidium iodide is a fluorescent probe that binds stoichiometrically to DNA by intercalating 
between the bases with little or no sequence preference, it is excited at 495 nm and emits at 639 nm. 
The intensity of fluorescence emitted is proportional to the amount of DNA present in each cell. 
 
PI fluorescence was analyzed by using a flow cytometer Epics XL MCL (Coulter), and cell cycle 
analysis was performed using the MCycle (Verity) and MODFIT 5.0 softwares. All experiments 
were repeated at least twice. 
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3.5 EGFR PHOSPHORILATION STATE ANALYSIS 
 
 
3.5.1 Treatments 
 
After 24 h of adhesion, HT-29 were serum starved for two days before being exposed to 2 µM 
FR18, dissolved in serum-free fresh medium, for 30 min. Cells were washed in RPMI 1640, treated 
for 30 min with 100 pM EGF and lysed directly in the culture plate. 
 
 
3.5.2 Protein extraction: whole cell  lysate 
 
Adherent cells were washed twice with 1 mL of cold PBS-1mM vanadate and lysed in 500 µL of 
RIPA buffer [10 mM Tris-HCl (Sigma-Aldrich, St. Louis, MO), pH 7.5, 150 mM NaCl, 1 mM NaF 
(Fluka), 1% EDTA modified with 1% Na-deoxycholate (Sigma-Aldrich, St. Louis, MO), 0.1% 
sodium dodecyl sulfate (SDS) (ICN Biomedicals, Irvine, CA), protease inhibitors (0.01 mg/mL 
aprotinin, 0.01 mg/mL antipain, 0.01 mg/mL leupeptin, 0.01 mg/mL pestatin) (Inalco, Milan, Italy), 
0.1 mM phenylmethyl sulfonyl fluoride (PMSF), 0.5 mM sodium vanadate (Sigma-Aldrich, St. 
Louis, MO)] and 500 µL of HNTG buffer [50mM HEPES (Sigma-Aldrich, St. Louis, MO) pH 7.4, 
150mM NaCl, 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO), 10% glycerol]. 
After 15 min at 4°C, the lysates were spun at 14,000 rpm at 4°C for 20 min. The supernatants were 
used as whole cell extracts. 
 
 
3.5.3 Determination of protein concentration  
 
Protein concentration was determined by using the Bradford protein determination method. First a 
calibration curve with known concentrations of BSA was prepared. Protein samples (BSA or cell 
lysates) were added with the Bradford reagent (Coomassie Brilliant Blue G-250) (Bio-Rad, 
Richmond, CA) and their absorbance at 595 nm was measured using an Uvikon 930 (Kontron) 
spectrophotometer. Protein concentration for each cell lysate was determined by interpolation of the 
absorbance on the calibration curve obtained from the samples at known protein concentration. 
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3.5.4 Immunoprecipitation and Western Blot 
 
Five hundred micrograms of proteins were immunoprecipitated overnight at 4°C with 1 µg of          
anti-EGFR monoclonal antibody (Biosource, Camarillo, CA) in 700 µL of lysis buffer.  
Protein A Sepharose CL-4B (Amersham, Pittsburg, PA) was activated by adding 1 mL of HCl      
(Carlo Erba, Milan, Italy) 1mM. The resin was left on ice for 20 min and washed thrice in 1 mM 
HCl and 0.1 M NaHCO3 buffer (Sigma-Aldrich, St. Louis, MO) in 0.5 M NaCl at pH 8, 
centrifuging each time for 3 min 3,000 g. The resin was finally resuspended at a concentration of    
6 mg/30 µL of bicarbonate buffer at pH 8.  
Previously obtained immune complexes were added to 6 mg of resin, kept in a shaker for 45 min at 
room temperature and precipitated at 13,000 g for 30 min. The obtained pellets were washed from 
any excess of extracted protein with 0.1 M potassium phosphate buffer (KH2PO4 / K2HPO4) at     
pH 8, centrifuging each time for 5 min at 10,000 g and subsequently resuspended in 20 µL of 
Sample buffer (65 mM Tris-HCl at pH 7.5, 65 mM β-mercaptoethnol, 1% SDS, 10% glycerol, 
0.001% bromophenol blue). Samples were heated for 5 minutes at 100 °C, cooled on ice, 
centrifuged for 30 sec at maximum speed and the supernatants were electrophoresed for 60 min on 
7.5% (w/v) polyacrylamide gels using 200 V constant voltage at +4°C. 
The running buffer was 0.025 M Trizma base (Sigma-Aldrich, St. Louis, MO), 0.192 M Glycine 
(Sigma-Aldrich, St. Louis, MO), 10% SDS (Sigma-Aldrich, St. Louis, MO) in H2O. 
The gel was maintained for 20 min in agitation in the transfer buffer consisting of 0.025 M Trizma 
base, 0.192 M Glycine, 10% methanol in double-distilled H2O. 
Simultaneously, the nitrocellulose membrane (Schleicher & Schuell BioScience, Keene, NH), was 
activated by a first wash of 5 min in double distilled H2O, and a second one in transfer buffer for        
20 min. 
Proteins were electrophoretically transferred to the nitrocellulose transfer membrane for 60 min 
using 100 V constant voltage at room temperature. 
The membrane was blocked in 0.1% PBS-Tween 20 (Sigma-Aldrich, St. Louis, MO) for 60 min at 
room temperature and incubated overnight at +4°C or 1 h at room temperature with                               
anti-phosphotyrosine monoclonal antibody (Upstate Biotechnology, Lake Placid, NY) diluted 
1:1,000 in 0.1% PBS-Tween 20. The membrane was washed in 0.1% PBS-Tween 20 (two times for 
a few seconds, once for 15 min, twice for 5 min), incubated for one hour, with a solution containing 
the appropriate horseradish peroxidase-linked secondary antibody (Amersham, Pittsburg, PA) 
diluted 1:20,000 in 0.1% PBS-Tween 20 and washed again with PBS-Tween 20. 
Immunoreactive bands were finally developed with SuperSignal West Dura Extended Duration 
chemiluminescent substrate according to the manufacturer’s protocol (Pierce, Rockford, IL). 
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3.6 EGF/EGFR COMPLEX INTERACTION STUDIES BY SURFACE PLASMON 
RESONANCE 
 
To study the EGF/EGFR complex interaction three different experimental approaches have been 
used. 
EGFR immobilisation, directly or via capturing antibodies, on a sensor chip and its interactions 
with EGF were studied. An EGFR over expressing human epidermoid carcinoma cell line, A431 
(2x106 EGFR molecules/cell) was used as receptor source [149, 150]. Also EGF was immobilised 
and its interaction with the receptor from A431 cell lysate was investigated.  
A commercially available purified EGF receptor (Sigma-Aldrich, St. Louis, MO) was subsequently 
immobilised on a sensor chip and its interaction with EGF was assayed. 
 
 
 
3.6.1 EGFR capturing from A431 total cell lysate and binding to EGF 
 
For EGF/EGFR interaction study, EGFR immobilisation from A431 cell lysate via two capturing 
antibodies that recognise its C-terminal region and a lipid bilayer environment reconstitution on the 
chip surface were investigated.  
 
 
Solubilization of EGFR receptors 
Approximately 107 cells were lysed in 1mL of RIPA modified buffer as described in chapter 3.5.2 
or in a buffer consisting of PBS, pH 7.4, 0.01 mg/mL of each protease inhibitor (aprotinin, antipain, 
leupeptin, pestatin), 0.1 mM phenylmethyl sulfonyl fluoride (PMSF), 0.5 mM sodium vanadate and 
1% Triton X-100 on a rocker for 45min at 4°C. Cell lysates were clarified using a tabletop 
centrifuge at 14,000 rpm for 30 min at 4°C and the supernatants containing the EGFR receptors 
were transferred to new tubes. 
 
 
Preparation of lipid/detergent-mixed micelle 
To prepare lipid/detergent-mixed micelles, aliquots of 2.5 mg of a lipid mixture containing 16.7% 
phosphatidylethanolamine, 10.6% phosphatidylserine, 9.6% phosphatidylcholine, 2.6% 
phosphatidic acid, 1.6% phosphatidyl inositol, 58.7% other lipids (Avanti Polar Lipids Inc., 
Alabaster, AL) were transferred into glass test tubes. A thin lipid film was formed on the glass wall 
by rotating the tube while evaporating the chloroform using a stream of nitrogen gas. Any 
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remaining chloroform was removed using overnight vacuum. To these dry lipid aliquots, 1ml of 
HBS buffer [10 mM HEPES (Sigma-Aldrich, St. Louis, MO), pH 7.4, and 0.15 M NaCl] 
supplemented with 30 mM n-Octyl-b-D-glucoside detergent (Anatrace, Maumee, OH) was added 
and the mixtures were vortex three times.  
 
 
EGFR capturing and interaction with EGF  
EGFR antibodies (abcam plc, Cambridge, UK and Santa Cruz Biotechnology, Santa Cruz, CA)  
were buffer changed in 10 mM sodium acetate at pH 5.0 and pH 4.5 respectively using the protein 
desalting spin columns (Pierce, Rockford, IL) according to manufacturer’s instruction and              
25 µg/mL of each antibody was immobilized on the chip by amine coupling.  
The sensor chip surface was activated by a 7 min injection of 0.1 M N-hydroxysuccinimide (NHS)   
(GE Healthcare, Uppsala, Sweden) mixed 50:50 with 0.4 M N-ethyl-N´-dimethylaminopropyl-
carbodiimide (EDC) (GE Healthcare, Uppsala, Sweden). Antibodies were injected on the surface 
for 7 minutes at 5 µL/min flow rate and the surface was subsequently deactivated by a 7 min 
injection of  1 M ethanolamine pH 8.5 (GE Healthcare, Uppsala, Sweden).  
Total cell lysate containing the EGFR was injected for 20 min at 5 µL/min flow rate across the 
antibodies immobilised surfaces on separate flow cells of the L1 chip employing the COINJECT 
function. In sequence with the receptor capture a lipid bilayer was reconstituted by injecting the 
lipid mixture for 10 min at 5 µL/min flow rate [151]. A reference surface (negative control) where 
solubilized receptor was not injected across the antibodies immobilised surface, followed by 
reconstitution was also included.  
 
Increasing concentrations 20 nM-1 µM of EGF (PreproTech, Rocky Hill, NJ) and HBS buffer 
(blank) were injected over the activated surfaces for 3 min at a flow rate of 30 µL/min in order to 
study EGF/EGFR interaction. EGF was allowed to dissociate for 10 min in absence of surface 
regeneration. 
All experiments were performed using a Biacore 2000 instrument (GE Healthcare, Uppsala, 
Sweden) equipped with an L1 sensor chip (GE Healthcare, Uppsala, Sweden) which consists of a 
thin gold-film covered with a carboxymethylated dextran-matrix modified with lipophilic 
substances (www.biacore.com) and the running buffer was HBS buffer.  
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3.6.2 EGF immobilization and binding to EGFR 
 
EGF was also immobilised on the sensor chip in order to investigate its interaction with EGFR 
present in two different cell lysates. 
 
Solubilization of EGFR receptors 
107 A431 cells were lysed in 1mL of PBS containing 10mM EDTA, 1mM PMSF, 0.1 mg/mL 
aprotinin and 1% TritonX-100 (bufferA) for 30 min on ice [152] or in 1 mL of 50mM Tris-HCl, pH 
7.4, 50 mM MgCl2, 10 µM sodium vanadate, 5 mg/mL aprotinin, 1 mM EDTA and 1mM PMSF 
(buffer B) for 20 min at +4°C and clarified by centrifugation at 10,000 rpm for 15 min at +4°C 
[153] and the supernatants containing the EGFR receptors were transferred to new tubes. 
 
EGF was buffer changed in 10 mM sodium acetate, pH 4.5 using the protein desalting spin columns 
(Pierce, Rockford, IL) and a 100 µg/mL solution was amine coupled on an L1 sensor chip for        
10 min at 5 µL/min of flow rate using a Biacore S51 instrument (GE Healthcare, Uppsala, Sweden) 
and HBS as running buffer. A reference surface (negative control) was activated and deactivated in 
the same way as the respective active surface.  
Total cell lysate containing the EGFR was injected for 20 min at 10 µL/min flow rate across the 
EGF immobilised surfaces. Subsequently a lipid bilayer was reconstituted by injecting the lipid 
mixture for 10 min at 10 µL/min flow rate (as described in chapter 3.6.1). 
 
 
3.6.3 Purified EGFR immobilization and binding to EGF 
 
Commercial EGFR isolated from A431 cells by affinity-purification (Sigma-Aldrich, St. Louis, 
MO) was reconstituted in 10% glycerol in sterile water, yielding a 278 µg/mL stock solution in           
50 mM HEPES, pH 7.6, 150 mM NaCl, 0.05% Triton X-100, 10% glycerol, 1 mM dithiothreitol 
and 10% trehalose. 
EGFR-stock diluted to 56 nM with 9 mM sodium acetate buffer, pH 5.0, 10% glycerol, 1 mM DTT 
and 0.05% TritonX-100 was immobilized on the chip by amine coupling as previously described. 
EGFR was injected on the sensor chip for 12 minutes at 5 µL/min flow rate. A reference surface 
was activated and deactivated in the same way as the respective active surface.  
 
To study the EGF/EGFR interaction, four consecutive running buffer (20 mM Tris-HCl, pH 7.4,       
150 mM NaCl, 1 mM EDTA, 0.05% TritonX-100, 1 mM DTT and 10% glycerol) cycles were run 
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on the sensor chip surface followed by triplicate injections of EGF for 7 min at 5 µL/min in order of 
increasing concentration (15 nM-2 µM). EGF was allowed to dissociate for 5 min before 
regenerating the chip surface for 1 min with 10 mM glycine, pH 2.0. Biacore S51 instrument 
equipped with L1 sensor chip was used. 
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4. RESULTS 
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4.1 CELL VIABILITY ASSESMENT 
 
To assess the cytotoxic effects of FR18 in our experimental model (HT-29), the dose inhibiting the 
growth of 50% of the cell population (IC50) was initially determined by MTT assay as described in 
section 3.2. 
After 24 h of adhesion, HT-29 cells were exposed to increasing concentrations of FR18                         
(10 nM-1.2 mM) and absorbance values obtained at 570 nm as a function of the logarithm of molar 
concentration of FR18 were reported in the chart below.  As shown in Figure 4.1, HT-29 cells were 
sensitive to FR18 with an approximate IC50 of 45.16-58.80 µM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Inhibitory effects of FR18 on HT-29 cells proliferation. Cells were incubated with increasing concentrations 
of FR18 for 24 h. The cell viability was determined by MTT assay. Data are shown as means ± SD (n = 3). 
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4.2 FR18 EFFECTS ON EGF/EGFR INTERACTION 
 
Fluorescence confocal microscopy was used to investigate specific binding of FR18 to EGFR. Due 
to the structural similarity to shikonin, it was assumed that FR18 would interfere with the binding 
mechanisms of EGF to its receptor. The experiments were therefore performed with a fluorescent 
EGF derivative (Alexa Fluor® 488 EGF) and the confocal microscopy analysis revealed that EGF 
and EGFR formed a complex localized in granules in the plasma membrane in EGF-stimulated 
serum-starved cells, whose presence greatly diminished in FR18-treated and EGF-stimulated      
HT-29. This indicated that concomitant treatment with FR18 and EGF prevented the complex 
formation (Figure 4.2.1). In addition, spectral imaging was applied to confirm and quantify the 
interference of FR18 on EGF/EGFR interaction. As shown in Figure 4.2.2, EGF-associated 
fluorescence signal decreased threefold in the presence of FR18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.1: Confocal laser-scanning micrographs and confocal spectral analysis of EGF and EGFR in control and 
FR18 treated cells. Staining of EGF (green fluorescence) and EGFR (red fluorescence) in control and in FR18 treated 
cells are shown in upper panels and in lower panels, respectively. Manders’ overlap coefficient of EGF signal 
coincident with EGFR signal is 0.43 in treated cells and 0.79 in untreated HT-29. The images were collected using a 
Nikon Plan Apo 60·, 1.4-NA oil immersion lens.  
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Figure 4.2.2: Spectral confocal imaging of EGF binding to EGFR. Left) Representative spectral micrographs, right) 
collected spectra from at least five cells for each acquisition. 
 
 
 
 
 
4.3 CELL CYCLE ANALYSIS AND APOPTOSIS EVALUATION 
 
To determine the effects of FR18 on the growth of HT-29, cells were treated for 24 hours with 
FR18 (1 nM-5 µM) or with an anti-EGFR monoclonal antibody that blocks the ligand binding site. 
Cells were permeabilized, incubated with RNase and labeled with propidium iodide, as described in  
section 3.4. 
The fluorescence associated with propidium iodide was analyzed using a flow cytometer Epics Elite 
(Coulter) equipped with an Argon ion laser. 
The cell cycle was analyzed using the software M Cycle (Verity) and MODFIT 5.0. 
FR18 treatment resulted in a dose-independent arrest in the S phase. In addition, an apoptotic peak 
was detected for higher concentrations (30 nM-5 µM). Peak average was 8.06% for 30 nM FR18 
treatment and increased to 26.06% for 5 µM (Figure 4.3). 
On the contrary, treatment of HT-29 cells with an anti-EGFR mAb that blocks the ligand binding 
site determined a cell cycle arrest in G0/G1 and did not induce apoptosis (Figure 4.3). 
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Figure 4.3: Flow cytometric analysis of HT-29 cells treated with FR18 or an anti-EGFR monoclonal antibody for 24 h. 
Cell cycle in phase S arrest and apoptosis were observed at concentrations ranging from 1 nM to 5 µM. In anti-EGFR 
monoclonal antibody treated samples instead, a proliferation arrest in G0/G1 was detected. 
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4.4 FR18 EFFECTS ON EGFR PHOSPHORILATION  
 
As binding of EGF caused EGFR activation through dimerization and phosphorylation of tyrosine 
residues in its cytoplasmatic domain immunoblot experiments with anti-phosphotyrosine antibody 
was performed. Treatment with EGF for 30 min of serum-starved HT-29 resulted in EGFR 
activation, and a comparable receptor phosphorylation pattern was recorded after exposure to EGF 
in combination with FR18 as shown in Figure 4.4. 
 
 
 
 
 
Figure 4.4: Effect of FR18 on EGFR phosphorylation. Serum-starved HT-29 cells were treated with 2 µM FR18 for 30 
min and then incubated with 100 pM EGF for 30 min. Cell lysates were immunoprecipitated with an anti-EGFR 
antibody and immunoblotted with an anti-phosphotyrosine antibody. Detection of immunoreactive bands was 
performed with secondary antibody conjugated with horseradish peroxidase and developed with a chemiluminescent 
system. 
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4.5 SPR STUDIES OF EGF/EGFR INTERACTION  
 
 
 
4.5.1 EGF binding to captured and reconstituted EGFR from A431 cell lysate 
 
For EGF receptor capturing on the L1 surface A431 cell lysate was used as receptor source. To 
form more active and oriented anti-EGFR antibody surfaces, amine coupling chemistry was used to 
immobilize both antibodies purchased from Abcam Plc (Cambridge, UK) and Santa Cruz 
Biotechnology (Santa Cruz, CA) at similar densities on the L1 chip surface resulting in a range of      
10-13 kRU.  
Across these antibody prepared surfaces A431 cell lysate was injected for 20 min, followed by an 
immediate reconstitution of lipids with a 10 min injection of 2.5 mM lipid mixture and 30 mM       
n-Octyl-b-D-glucoside detergent using the COINJECT function, resulting in both cases where cell 
lysate in RIPA and PBS buffer were used as receptor source, in 600-750 RU of density. 
To verify the presence of captured and reconstituted EGF receptor, increasing concentrations of 
EGF (20 nM-1 µM) and HBS buffer (blank) injections were run though the active and reference 
surfaces for 3 min at  30 µL/min of flow rate and the dissociation was followed for 10 min in 
absence of surface regeneration. 
As shown in figure 4.5.1-1 no binding to the active or to the reference surface was observed 
indicating that very low quantities or inactive EGFR capture had occurred when cell lysate in PBS 
buffer was used as EGFR source. 
EGF binding to the active surfaces, obtained using cell lysate in RIPA buffer and anti-EGFR from 
Santa Cruz Biotechnology (Santa Cruz, CA) for EGFR capturing and reconstitution, was observed 
instead at very low levels. A maximum response of 5 RU was recorded and only for EGF 
concentrations ranging from 20-160 nM (Figure 4.5.1-2), indicating that the quantity of active 
EGFR captured and reconstituted on the chip surface was extremely low. All experiments were 
performed using a Biacore 2000 instrument and shown sensograms were reference and blank 
subtracted. 
 
 
 
 
 
 
 
 55 
a) 
-20
-15
-10
-5
0
5
10
15
20
-100 0 100 200 300 400 500 600 700 800
Tim e s
R
e
sp
o
n
s
e
RU
EGF 20nM
EGF 40nM
EGF 80nM
EGF 160nM
EGF 320nM
EGF 500nM
EGF 640nM
EGF 1000nM
 
b) 
-20
-15
-10
-5
0
5
10
15
20
-100 0 100 200 300 400 500 600 700 800
Tim e s
R
es
po
n
se
RU
EGF 20nM
EGF 40nM
EGF 80nM
EGF 160nM
EGF 320nM
EGF 500nM
EGF 640nM
EGF 1000nM
 
 
 
Figure 4.5.1-1: EGF binding to active surfaces obtained using cell lysate in PBS buffer as EGFR source and anti-EGFR 
purchased from a) abcam plc (Cambridge, UK) and b) Santa Cruz Biotechnology (Santa Cruz, CA) for receptor 
capturing.   
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Figure 4.5.1-2: EGF binding to active surfaces obtained using cell lysate in RIPA buffer as EGFR source and               
anti-EGFR purchased from a) abcam plc (Cambridge, UK) and b) Santa Cruz Biotechnology (Santa Cruz, CA) for 
receptor capturing and reconstitution. Only 5 RU of not concentration-dependent binding response was observed when 
anti-EGFR antibody from Santa Cruz Biotechnology (Santa Cruz, CA) was used. 
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4.5.2 Immobilised EGF interaction with A431 cell lysate  
 
For EGF/EGFR complex interaction studies, EGF was also used for EGFR capturing on L1 sensor 
chip. EGF was immobilised on the sensor chip by amine coupling chemistry and its interaction with 
two different A431 total cell lysate (EGFR source) was examined. Biacore S51 instrument was used 
for all experiments. 
EGF was buffer changed in 10 mM sodium acetate buffer, pH 4.5 and a solution of 100 µg/mL was 
injected on the chip surface for 10 min at 5 µL/min of flow rate resulting in 800 RU of 
immobilisation response as shown in figure 4.5.2-1. 
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Figure 4.5.2-1: Amine coupling of EGF on L1 sensorchip. A) Baseline level. B) Activation of the sensor surface with 
0.4 M EDC/0.1 M NHS for 7 min. C) Binding curve of 100 µg/mL EGF in 10 mM sodium acetate buffer, pH 4.5 
injected for       10 min. D) Deactivation of the sensor surface with 1 M ethanolamine for 7 min. E) Immobilized amount 
of EGF (E-A). 
 
 
 
 
 
The binding levels of A431 cell lysate in buffer A or B (chapter 3.6.2) followed by 10 min of lipid 
reconstitution resulted to be much higher on the reference (no EGF immobilised) than on the active 
surfaces, respectively 4375 RU vs 2180 RU for cell lysate in buffer A and 2462 RU vs 1528 RU for 
cell lysate in buffer B. As shown in Figure 4.5.2-2, a totally non specific binding of the cell lysate to 
the sensor chip surface was detected for both utilised cell lysates.  
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Figure 4.5.2-2: Rapresentative sensograms of  reference a) and  active b) surfaces showing A431 cell lysate binding to 
immobilised EGF on L1 sensor chip. A) Baseline level. B) Cell lysate injection. C) Lipid mixture injection. D) Binding 
levels (D-A).  
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4.5.3 EGF binding to amine coupled purified EGFR 
 
As previously described experiments for EGF/EGFR interaction studies using A431 cell lysate as 
receptor source didn’t give any promising result, we decided to use a commercially available 
purified form of EGFR purchased from Sigma-Aldrich (St. Louis, MO).  
Amine coupling chemistry as described in chapter 3.6.3 was used for the immobilisation on the 
sensor chip surface and about 3500 RU of EGFR could be immobilized on L1 chip. 
The active and reference surfaces were previously conditioned by four consecutive running buffer 
injections for 7 min at 5 µL/min and the blank response was obtained. 
Increasing concentrations of EGF were subsequently injected at the same conditions over the chip 
surface. An obvious association to the immobilised EGFR was observed from reference and blank 
subtracted sensograms (Figure 4.5.3). 
 
 
 
-20
0
20
40
60
80
100
-200 0 200 400 600 800 1000 1200
Tim e s
R
es
p.
 
D
iff
.
RU
EGF 15nM EGF 15nM EGF 15nM EGF 30nM EGF 30nM EGF 30nM EGF 63nM EGF 63nM EGF 63nM EGF 125nM EGF 125nM EGF 125nM EGF 250nM
EGF 250nM EGF 250nM EGF 500nM EGF 500nM EGF 500nM EGF 1uM EGF 1uM EGF 1uM EGF 2uM EGF 2uM EGF 2uM
 
 
Figure 4.5.3: BIAevaluation curve fit for EGF binding to amine coupled EGFR. Five consecutive blank cycles were run 
followed by triplicate injections of EGF for 7 min at 5 µL/min in order of increasing concentration. EGF was allowed to 
dissociate for 5 min before the surface was regenerated for 1 min with 10 mM glycine, pH 2.0. 
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EGF binding was concentration dependent and EGF dissociation was observed after 5 min. Kinetic 
parameters regarding association (ka = 1.18 ± 0.28 x 103 M-1sec-1) as well as dissociation (kd = 4.24 
± 0.31 x 10-4 sec-1) rate constants were calculated using BIAevaluation 4.1 software and the 
calculated KD (368 ± 0.65 nM) values, assuming an 1:1 Langmuir binding model, were comparable 
to those reported in literature for EGF binding to the extracellular ligand binding domain of EGFR 
[154]. The binding curves behaviour revealed that the association of EGF to the receptor probably 
triggers higher order events, such as conformational changes, which could interfere with the 
complex formation. 
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4. DISCUSSION 
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The use of agents that target EGFR in cancer therapy has been proposed, and these novel treatment 
options have been components of an ongoing revolution in cancer therapy, holding the promise of 
fulfilling significant unmet needs in many tumor types. Of the various EGFR-targeted agents, the 
most promising and well studied are the mAbs and the small-molecule EGFR tyrosine kinase 
inhibitors. These agents have shown substantial differences in dosing requirements and toxicity 
profiles. Nevertheless, both of them have demonstrated little utility as therapeutic agents: 
monoclonal antibodies are effective at toxic doses, while tyrosine kinase inhibitors result inefficient 
in colon tumors. The results presented in this thesis work describe the identification of a novel 
naphthoquinone molecule, FR18, which targets EGFR and induces cell death of HT-29 cells. 
As shown in Figure 4.1, the cells are sensitive to FR18 with an approximate IC50 ranging from 
45.16 to 58.80 µM. The results obtained in confocal laser scanning microscopy analysis suggest that 
FR18 binds competitively to the extracellular domain of the receptor. EGF and EGFR form a 
complex localized in granules in the plasma membrane in EGF-stimulated serum-starved cells, 
whose presence greatly diminishes in FR18-treated and EGF-stimulated HT-29; the EGF-associated 
fluorescence signal, in fact, decreases threefold in the presence of FR18, as shown in Figures 4.2.1 
and 4.2.2. 
This interaction does not prevent the receptor tyrosine kinase activation, assessed in terms of 
tyrosine phosphorylation (Figure 4.4), and causes apoptotic EGFR-mediated intracellular signaling 
(Figure 4.3). 
Apoptotic peaks are detected for higher FR18 concentrations (30 nM-5 µM) with a peak average of 
8.06% for 30 nM FR18 treatment which increases to 26.06% for 5 µM (Figure 4.3). Furthermore, 
the flow cytometric analysis shows that FR18 treatment induces an arrest in the S phase of the cell 
cycle and that this event together with the observed apoptotic death,  is not dose dependent     
(Figure 4.3). These results show that FR18, a synthetic small molecule that interferes with EGF 
binding to EGFR, is able to induce apoptosis in HT-29 cells, suggesting a potential therapeutic 
application of this compound. 
The second aspect of this thesis work concerned the study of EGF/EGFR complex interaction, an 
important system highly perturbed in several tumor types, by the use of surface plasmon resonance 
biosensors in order to acquire significant general knowledge that can help the design of new drugs 
intended to interfere with the EGFR binding activity. 
Previously, EGF/EGFR complex interaction was investigated using the total cell lysate of A431 as 
receptor source. In fact, EGFR immobilisation on the sensor chip surface via two capturing 
antibodies that recognise its C-terminal region and a lipid bilayer environment reconstitution were 
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investigated. Also EGF was immobilised in order to evaluate its interaction with the EGFR present 
in A431 cell lysate.  
Both these experimental approaches didn’t give any positive results.  We weren’t able to capture the 
EGFR on the sensor chip surface probably because of the high composition complexity of A431 
cell lysates or because of the improper SPR experimental conditions which negatively affected the 
procedure. Even when EGF was immobilised on the sensor chip surface for EGFR capturing from 
A431 cell lysates the results were unsatisfactory, thus indicating that a proper EGFR purification 
step is necessary for this kind of experimental design. 
Subsequently a commercially available purified EGF receptor (Sigma-Aldrich, St. Louis, MO) was 
immobilised on the sensor chip resulting in about 3500 RU of response. The increasing 
concentrations of EGF injected over the immobilised receptor revealed that the EGFR was able to 
bind to EGF with a calculated KD value of 368 ± 0.65 nM, assuming a 1:1 Langmuir binding model, 
which is in line with those reported in the literature. The obtained results indicate that the 
association of EGF to the receptor probably triggers higher order events, such as conformational 
changes, which could probably interfere with the complex formation, therefore binding specificity 
as well as improvement of the amount of immobilised EGFR able to interact with EGF represent 
important steps for better understanding this challenging but crucial receptor-ligand complex 
interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 64 
 
6. BIBLIOGRAPHY 
 
 
1 .  Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. (2009) Cancer statistics, 2009. CA Cancer J 
Clin 59: 225-49. 
 
2 .  Levine JS and Ahnen DJ. (2006) Adenomatous polyps of the colon. NEngl J Med 355: 2551–7. 
 
3 .  Worthley DL, Whitehall VL, Spring KJ, Leggett BA. (2007) Colorectal carcinogenesis: Road 
maps to cancer. World J Gastroenterol 13: 3784-91. 
 
4 .  Melissa M, Ahmedin J, Robert AS, Elizabeth W. (2009) Worldwide Variations in Colorectal 
Cancer. CA Cancer J Clin 59: 366-78. 
 
5 .  Winawer SJ and Sherlock P. (2007) Colorectal cancer screening. Best Practice & Res Clin 
Gastroenterol 21:1031-48.   
 
6 .  Peltomaki P. (2003) Role of DNA mismatch repair defects in the pathogenesis of human cancer. 
J Clin Oncol 21: 1174–9. 
 
7 .  Kinzler KW and Vogelstein B. (2002) Colorectal tumors. In Vogelstein B and Kinzler KW eds., 
The Genetic Basis of Human Cancer (2nd ed.) McGraw-Hill, New York. 
 
8 .  McLellan EA and Bird RP. (1988) Specificity Study to Evaluate Induction of Aberrant Crypts in 
murine Colons. Cancer Res 48: 6183-6. 
 
9 .  Cheng L and Lai MD. (2003) Aberrant crypt foci as microscopic precursors of colorectal cancer. 
World J Gastroenterol 9: 2642-9. 
 
1 0 .  Hurlstone DP and Cross SS. (2005) Role of aberrant crypt foci detected using                               
high-magnification-chromoscopic colonoscopy in human colorectal carcinogenesis. J 
Gastroenterol Hepatol 20: 173-81. 
 
1 1 .  Takata M, Yao T, Nishiyama KI, Nawata H, Tsuneyoshi M. (2003) Phenotypic alteration in 
malignant transformation of colonic villous tumours: with special reference to a comparison with 
tubular tumours. Histopathology 43: 332-9. 
 
1 2 .  Kumar V and Robbins SL. (2007) Robbins basic pathology. (8th ed.) Saunders/Elsevier, 
Philadelphia. 
 
1 3 .  Cappell MS. (2005) From colonic polyps to colon cancer: pathophysiology, clinical 
presentation, and diagnosis. Clin Lab Med 25: 135–77. 
 
1 4 .  Galiatsatos P and Foulkes WD. (2006) Familial Adenomatous Polyposis. The American Journal 
of Gastroenterology 101: 385–98. 
 
1 5 .  Kinzler KW and Vogelstein B. (1996) Lessons from hereditary colorectal cancer. Cell 87: 159-
70. 
 65 
1 6 .  Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, 
Kinzler KW. (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359: 
235-7. 
 
1 7 .  Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, Kinzler KW. (1994) 
Molecular determinants of dysplasia in colorectal lesions. Cancer Res 54: 5523-6. 
 
1 8 .  Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV, Gallinger S. (1994) Somatic APC 
and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 54: 5527-
30. 
 
1 9 .  Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, 
Clevers H. (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in   
APC-/- colon carcinoma. Science 275: 1784-7. 
 
2 0 .  Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. (1997) 
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. 
Science 275: 1787-90. 
 
2 1 .  Smits R, Kielman MF, Breukel C, Zurcher C, Neufeld K, Jagmohan-Changur S, et al. (1999) 
Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli 
protein involved in tumorigenesis and development. Genes Dev 13: 1309-21. 
 
2 2 .  Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. (1998) Mutational analysis of the    
APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58:1130-4. 
  
2 3 .  Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, et al. (2000) AXIN1 mutations 
in hepatocellular carcinomas, and growth suppression in cancer cells by  virus-mediated transfer 
of AXIN1. Nat Genet 24: 245-50. 
 
2 4 .  Clevers H. (2000) Axin and hepatocellular carcinomas. Nat Genet 24: 206-8. 
 
2 5 .  Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T, Miki Y, Mori T, 
Nakamura Y. (1992) Somatic mutations of the APC gene in colorectal tumors: mutation cluster 
region in the APC gene. Hum Mol Genet 1: 229-33. 
 
2 6 .  Knudson AG Jr. (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad 
Sci U S A 68: 820-3. 
 
2 7 .  Lamlum H, Ilyas M, Rowan A, Clark S, Johnson V, Bell J, Frayling I, et a.. (1999) The type of 
somatic mutation at APC in familial adenomatous polyposis is determined by the site of the 
germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med 5: 1071-5. 
 
2 8 .  Albuquerque C, Breukel C, van der Luijt R, Fidalgo P, Lage P, Slors FJ, et al. (2002) The 'just-
right' signaling model: APC somatic mutations are selected based on a specific level of 
activation of the beta-catenin signaling cascade. Hum Mol Genet 11:1549-60. 
 
2 9 .  Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. (1987) Detection of high incidence 
of K-ras oncogenes during human colon tumorigenesis. Nature 327: 298-303. 
 
 66 
3 0 .  Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, 
White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumor development. N 
Engl J Med 319: 525-32. 
 
3 1 .  Beach R, Chan AO, Wu TT, White JA, Morris JS, Lunagomez S, Broaddus RR, Issa JP, 
Hamilton SR, Rashid A (2005) BRAF mutations in aberrant crypt foci and hyperplastic 
polyposis. Am J Pathol 166: 1069-75. 
 
3 2 .  Kim EC and Lance P. (1997) Colorectal polyps and their relationship to cancer. Gastroenterol 
Clin North Am 26: 1-17. 
 
3 3 .  Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R (1989) 
Allelotype of colorectal carcinomas. Science 244: 207-11. 
 
3 4 .  Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B, Hamilton 
SR (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 
331: 213-21. 
 
3 5 .  Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, Tessier-Lavigne M. 
(1996) Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell 87: 175-85. 
 
3 6 .  Cho KR, Oliner JD, Simons JW, Hedrick L, Fearon ER, Preisinger AC, Hedge P, Silverman 
GA, Vogelstein B. (1994) The DCC gene: structural analysis and mutations in colorectal 
carcinomas. Genomics 19: 525-31. 
 
3 7 .  Heldin CH, Miyazono K, ten Dijke P. (1997) TGF-beta signaling from cell membrane to 
nucleus through SMAD proteins. Nature 390: 465-71. 
 
3 8 .  Duff EK and Clarke AR. (1998) Smad4 (DPC4)--a potent tumour suppressor? Br J Cancer 78: 
1615-9. 
 
3 9 .  Baker SJ, Fearon ER, Nigro JM, Hamilton SR, et al. (1989) Chromosome 17 deletions and p53 
gene mutations in colorectal carcinomas. Science 244: 217-21. 
 
4 0 .  Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, et al. (1990) p53 gene 
mutations occur in combination with 17p allelic deletions as late events in colorectal 
tumorigenesis. Cancer Res  50: 7717-22. 
 
4 1 .  LaneDP. (1992) Cancer. p53, guardian of the genome. Nature 358: 15-6. 
 
4 2 .  Waldman T, Kinzler KW, Vogelstein B. (1995) p21 is necessary for the p53-mediated G1 arrest 
in human cancer cells. Cancer Res  55: 5187-90.  
 
4 3 .  Burns TF and El-Deiry WS. (1999) The p53 pathway and apoptosis. J Cell Physiol 181: 231-9. 
 
4 4 .  Ohue M, Tomita N, Monden T, Fujita M, Fukunaga M, Takami K, Yana I, Ohnishi T, et al. 
(1994) A frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res 54: 
4798-804. 
 
 67 
4 5 .  Yamaguchi A, Makimoto K, Goi T, Takeuchi K, Maehara M, Isobe Y, Nakagawara G. (1994) 
Overexpression of p53 protein and proliferative activity in colorectal adenoma. Oncology 51: 
224-7. 
 
4 6 .  Kaklamanis L, Gatter KC, Mortensen N, Baigrie RJ, Heryet A, Lane DP, Harris AL. (1993) p53 
expression in colorectal adenomas. Am J Pathol 142: 87-93. 
 
4 7 .  Kaserer K, Schmaus J, Bethge U, Migschitz B, Fasching S, Walch A, Herbst F, et al. (2000) 
Staining patterns of p53 immunohistochemistry and their biological significance in colorectal 
cancer. J Pathol 190: 450-6. 
 
4 8 .  Boland CR, Sato J, Appelman HD, Bresalier RS, Feinberg AP. (1995) Microallelotyping defines 
the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer 
progression. Nat Med 1: 902-9. 
 
4 9 .  Lengauer C, Kinzler KW, Vogelstein B. (1998) Genetic instabilities in human cancers. Nature 
396: 643–9. 
 
5 0 .  Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. (1993) Ubiquitous somatic 
mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. 
Nature 363: 558–61. 
 
5 1 .  Thibodeau SN, Bren G, Schaid D. (1993) Microsatellite instability in cancer of the proximal 
colon. Science 260: 816–9. 
 
5 2 .  Lengauer C, Kinzler KW, Vogelstein B.  (1997) Genetic instability in colorectal cancers. Nature 
386: 623–7. 
 
5 3 .  Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, Schorderet D, Bosman FT, 
Chaubert P. (2001) Methylation silencing and mutations of the p14ARF and p16NK4A genes in 
colon cancer. Lab Invest 81:217–29. 
 
5 4 .  Shannon BA and Iacopetta BJ. (2001) Methylation of the hMLH1, p16, and MDR1 genes in 
colorectal carcinoma: associations with clinicopathological features. Cancer Lett 167: 91–7. 
 
5 5 .  Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Göttlicher M. (2004) Induction of 
HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell  5: 455-63. 
 
5 6 .  Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, et al. (2006) Histone deacetylase 3 
(HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are 
deregulated in human colon cancer. J Biol Chem 281:13548-58.  
 
5 7 .  Dukes CE. (1932) The classification of cancer of the rectum. Journal of Pathol Bacteriol 35: 
323 
 
5 8 .  Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, and Loscalzo J. (2008) 
Harrison's Principles of Internal Medicine. (17ed.) McGraw-Hill, USA. 
 
5 9 .  Smith AJ, Driman DK, Spithoff K, Hunter A, McLeod RS, Simunovic M, Langer B. (2010) 
Guideline for optimization of colorectal cancer surgery and pathology. J Surg Oncol 101: 5-12. 
 68 
 
6 0 .  Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ (2007) Adjuvant Treatment of Colorectal 
Cancer. CA Cancer J Clin 57: 168-85 
 
6 1 .  Asmis TR and Saltz S. (2008) Systemic Therapy for Colon Cancer. Gastroenterol Clin N Am 7: 
287–95. 
 
6 2 .  Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. (1993) Randomised comparison of 
combination chemotherapy plus supportive care with supportive care alone in patients with 
metastatic colorectal cancer. BMJ 306: 752–5. 
 
6 3 .  Nordic Gastrointestinal Tumor Adjuvant Therapy Group. (1992) Expectancy or primary 
chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J 
Clin Oncol 10: 904–11. 
 
6 4 .  Ragnhammer P, Hafström L, Nygren P, Glimelius B for the SBU group. (2001) A systematic 
overview of chemotherapy effects in colorectal cancer. Acta Oncol 40: 282–308. 
 
6 5 .  Krueger GM, Alexander LL, Whippen DA, Balch CM. (2006) Arnoldus Goudsmit, MD, PhD: 
chemotherapist, visionary, founder of the American Society of Clinical Oncology, 1909–2005. J 
Clin Oncol 24: 4033–6. 
 
6 6 .  Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, et al. 
(2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: 
a randomized GERCOR study. J Clin Oncol 22: 229–37. 
 
6 7 .  Colucci G, Gebbia V, Paoletti G, et al. (2005) Phase III randomized trial of FOLFIRI versus 
FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo 
Oncologico Dell’Italia Meridionale. J Clin Oncol 23: 4866–75. 
 
6 8 .  Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan, 
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–42. 
 
 
6 9 .  Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. (2004) Phase II trial of cetuximab in patients with 
refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 
1201–8. 
 
7 0 .  Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab plus 
irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–45. 
 
7 1 .  Van Cutsem E, Peeters M, Siena S, et al. (2007) Open-label phase III trial of panitumumab plus 
best supportive care compared with best supportive care alone in patients with chemotherapy 
refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–64. 
 
7 2 .  Olayioye MA, Neve RM, Lane HA, Hynes NE. (2000) The ErbB signaling network: receptor 
heterodimerization in development and cancer. EMBO Journal 19:3159-67. 
 
7 3 .  Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, et al. (1996) A hierarchical 
network of interreceptor interactions determines signal transduction by Neu differentiation 
factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-87. 
 69 
 
7 4 .  Meyerhardt JA, Kwok A, Ratain MJ, McGovren JP, Fuchs CS. (2004) Relationship of baseline 
serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic 
colorectal cancer. J Clin Oncol 22:1439–46. 
 
7 5 .  Cummings RD, Soderquist AM, Carpenter G. (1985) The oligosaccharide moieties of the 
epidermal growth factor receptor in A-431 cells. Presence of complextype N-linked chains that 
contain terminal N-acetylgalactosamine residues. J Biol Chem 260: 11944-52. 
 
7 6 .  Ward CW and Garrett TP. (2001) The relationship between the L1 and L2 domains of the 
insulin and epidermal growth factor receptors and leucine-rich repeat modules. BMC 
Bioinformatics 2: 4. 
 
7 7 .  Lax I, Fischer R, Ng C, Segre J, Ullrich A, Givol D, Schlessinger J. (1991) Noncontiguous 
regions in the extracellular domain of EGF receptor define ligand-binding specificity. Cell Regul 
2: 337-45. 
 
7 8 .  Ward CW, Hoyne PA, Flegg RH. (1995) Insulin and epidermal growth factor receptors contain 
the cysteine repeat motif found in the tumor necrosis factor receptor. Proteins 22: 141-53. 
 
7 9 .  Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, et al. (2003) EGF activates its 
receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11: 507-17. 
 
8 0 .  Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, et al. (2002) Crystal structure of the 
complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-
87. 
 
8 1 .  Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, et al. (2002) Crystal structure of a 
truncated epidermal growth factor receptor extracellular domain bound to transforming growth 
factor alpha. Cell 110: 763-73. 
 
8 2 .  Stroud RM and Wells JA. (2004) Mechanistic diversity of cytokine receptor signaling across 
cell membranes. Sci STKE 2004, re7. 
 
8 3 .  Dawson JP, Berger MB, Lin CC, Schlessinger J, Lemmon MA, et al. (2005) Epidermal growth 
factor receptor dimerization and activation require ligand-induced conformational changes in the 
dimer interface. Mol Cell Biol 25: 7734-42. 
 
8 4 .  Berezov A, Chen J, Liu Q, Zhang HT, Greene MI, et al. (2002) Disabling receptor ensembles 
with rationally designed interface peptidomimetics. J Biol Chem 277: 28330-9. 
 
8 5 .  Saxon ML and Lee DC. (1999) Mutagenesis reveals a role for epidermal growth factor receptor 
extracellular subdomain IV in ligand binding. J Biol Chem 274: 28356-62. 
 
8 6 .  Dawson JP, Bu Z, Lemmon MA. (2007) Ligand-Induced Structural Transitions in ErbB 
Receptor Extracellular Domains. Structure 15: 942-54. 
 
8 7 .  Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, et al. (2003) An open-and-shut 
case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12: 541-52. 
 
 70 
8 8 .  Mattoon D, Klein P, Lemmon MA, Lax I, Schlessinger J. (2004) The tethered configuration of 
the EGF receptor extracellular domain exerts only a limited control of receptor function. Proc 
Natl Acad Sci U S A 101: 923-8. 
 
8 9 .  Walker F, Orchard SG, Jorissen RN, Hall NE, Zhang HH, et al. (2004) CR1/CR2 interactions 
modulate the functions of the cell surface epidermal growth factor receptor. J Biol Chem 279: 
22387-98. 
 
9 0 .  Johns TG, Mellman I, Cartwright GA, Ritter G, Old LJ, et al. (2005) The antitumor monoclonal 
antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface 
when cells overexpress  the receptor. Faseb J 19: 780-2. 
 
9 1 .  Whitson KB, Whitson SR, Red-Brewer ML, McCoy AJ, Vitali AA, et al. (2005) Functional 
effects of glycosylation at Asn-579 of the epidermal growth factor receptor. Biochemistry 44: 
14920-31. 
 
9 2 .  Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. (2006) An allosteric mechanism for 
activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-49. 
 
9 3 .  Gotoh N, Tojo A, Hino M, Yazaki Y, Shibuya M. (1992) A highly conserved tyrosine residue at 
codon 845 within the kinase domain is not required for the transforming activity of human 
epidermal growth factor receptor. Biochem Biophys Res Commun 186: 768-74. 
 
9 4 .  Erba EB, Matthiesen R, Bunkenborg J, Schulze WX, Di Stefano P, et al. (2007) Quantitation of 
multisite EGF receptor phosphorylation using mass spectrometry and a novel normalization 
approach. J Proteome Res 6: 2768-85. 
 
9 5 .  Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, et al. (2006) The complexity of 
targeting EGFR signaling in cancer: from expression to turnover. Biochim Biophys Acta 1766: 
120-39. 
 
9 6 .  Schulze WX, Deng L, Mann M. (2005) Phosphotyrosine interactome of the ErbB-receptor 
kinase family. Mol Syst Biol 1: 2005.0008. 
 
9 7 .  Hynes NE and Lane HA (2005) ERBB receptors and cancer: the complexity of targeted 
inhibitors. Nat Rev Cancer 5: 341-54. 
 
9 8 .  Katso R, Okkenhaug K, Doval DC et al. (2001) Cellular function of phosphoinositide 3-kinases: 
implications for development, homeostasis, and cancer. Cell Dev Biol 17: 615-75. 
 
9 9 .  Downward J. PI3-kinase, Akt, and cell survival. (2004) Semin Cell Dev Biol 15:177-82. 
 
1 0 0 .  Yu H and Jove R. The STATs of cancer - new molecular targets come of age. (2004) Nature 
Rev Cancer 4: 97-105. 
 
1 0 1 .  Bowman T, Garcia R, Turkson J, Jove R. (2000) STATs in oncogenesis. Oncogene 19: 2474-88. 
 
1 0 2 .  Buettner R, Mora LB, Jove R. (2002) Activated STAT signaling in human tumors provides 
novel molecular targets for therapeutic intervention. Clin Cancer Res  8: 945-54. 
 
 71 
1 0 3 .  Bromberg J and Darnell JE Jr. (2000) The role of STATs in transcriptional control and their 
impact on cellular function. Oncogene 19: 2468-73. 
 
1 0 4 .  Levy DE and Darnell JE Jr. (2002) Stats: transcriptional control and biological impact. Nature 
Rev Mol Cell Biol 3: 651-62. 
 
1 0 5 .  Yarden Y and Sliwkowski MX. (2001) Untangling the ErbB signaling network. Nat Rev Mol 
Cell Biol 2: 127-37. 
 
1 0 6 .  Carpenter G. (2003) Nuclear localization and possible functions of receptor tyrosine kinases. 
Curr Opin Cell Biol 15: 143-8. 
 
1 0 7 .  Wiley HS. (2003) Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 
284: 78-88. 
 
1 0 8 .  Stoscheck CM, and Carpenter G. (1984) Characterization of the metabolic turnover of epidermal 
growth factor receptor protein in A-431 cells. J Cell Physiol 120: 296-302. 
 
1 0 9 .  Waterman H, Sabanai I, Geiger B, Yarden Y. (1998) Alternative intracellular routing of ErbB 
receptors may determine signaling potency. J Biol Chem 273: 13819-27. 
 
1 1 0 .  Herbst JJ, Opresko LK, Walsh BJ, Lauffenburger DA, Wiley HS. (1994) Regulation of 
postendocytic trafficking of the epidermal growth factor receptor through endosomal retention. J 
Biol Chem 269: 12865-73. 
 
1 1 1 .  Futter CE, Pearse A, Hewlett LJ, Hopkins CR. (1996) Multivesicular endosomes containing 
internalized EGF-EGF receptor complexes mature and then fuse directly with lysosomes. J Cell 
Biol 132: 1011-23. 
 
1 1 2 .  Chen WS, Lazar CS, Poenie M, Tsien RY, Gill GN, et al. (1987) Requirement for intrinsic 
protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 328: 820-3. 
 
1 1 3 .  Schmidt MH, Furnari FB, Cavenee WK, Bogler O. (2003) Epidermal growth factor receptor 
signaling intensity determines intracellular protein interactions, ubiquitination, and 
internalization. Proc Natl Acad Sci U S A 100: 6505-10. 
 
1 1 4 .  Wang Q, Villeneuve G, Wang Z. (2005) Control of epidermal growth factor receptor 
endocytosis by receptor dimerization, rather than receptor kinase activation. EMBO Rep 6: 942-
8. 
 
1 1 5 .  Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, et al. (2003) Cbl-mediated ubiquitinylation 
is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for 
endocytosis. J Biol Chem 278: 28950-60. 
 
1 1 6 .  Huang F, Kirkpatrick D, Jiang X, Gygi S, Sorkin A. (2006) Differential regulation of EGF 
receptor internalization and degradation by multiubiquitination within the kinase domain. Mol 
Cell 21: 737-48. 
 
1 1 7 .  Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, et al. (1998) c-Cbl/Sli-1 regulates 
endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 12: 
3663-74. 
 72 
 
1 1 8 .  Haugh JM, Huang AC, Wiley HS, Wells A, Lauffenburger DA. (1999) Internalized epidermal 
growth factor receptors participate in the activation of p21(ras) in fibroblasts. J Biol Chem 274: 
34350-60. 
 
1 1 9 .  Wang Y, Pennock S, Chen X, Wang Z. (2002) Endosomal signaling of epidermal growth factor 
receptor stimulates signal transduction pathways leading to cell survival. Mol Cell Biol 22: 7279-
90. 
 
1 2 0 .  Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. (2003) Coregulation of epidermal 
growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: 
quantitative analysis of HER2 overexpression effects. Cancer Res 63: 1130-1137. 
 
1 2 1 .  Wiley HS, Shvartsman SY, Lauffenburger DA. (2003) Computational modeling of the EGF-
receptor system: a paradigm for systems biology. Trends Cell Biol 13: 43-50. 
 
1 2 2 .  Carpenter G. (2000) The EGF receptor: a nexus for trafficking and signaling. Bioessays 22: 697-
707. 
 
1 2 3 .  de Larco JE and Todaro GJ. (1978) Epithelioid and fibroblastic rat kidney cell clones: epidermal 
growth factor (EGF) receptors and the effect of mouse sarcoma virus transformation. J Cell 
Physiol 94: 335-42. 
 
1 2 4 .  Holbro T, Civenni G, Hynes NE. (2003) The ErbB receptors and their role in cancer 
progression. Exp Cell Res 284: 99-110. 
 
1 2 5 .  Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Oku N, Miyazawa K, et al. (1994) Tyrosine 
Phosphorylation of β-Catenin and Plakoglobin Enhanced by Hepatocyte Growth Factor and 
Epidermal Growth Factor in Human Carcinoma Cells. Cell Adhes Commun 1: 295-305. 
 
1 2 6 .  Daniel JM and Reynolds AB. (1997) Tyrosine phosphorylation and cadherin/catenin function. 
Bioessays 19: 883-91. 
 
1 2 7 .  Herbst RS and Shin DM. (2002) Monoclonal antibodies to target epidermal growth factor 
receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94: 1593-611. 
 
1 2 8 .  Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, et al. (2007) Translational up-
regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its 
overexpression in human cancer. Proc Natl Acad Sci U S A 104: 13092-7. 
 
1 2 9 .  McKaya JA, Murraya LJ, Curranb S, Rossb VG, C Clarka, Murrayb GI, Cassidya J, McLeoda 
HL (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and 
lymph node metastases. EJC 38: 2258-64. 
 
1 3 0 .  Nicholson RI, Gee JM, Harper ME. (2001) EGFR and cancer prognosis. Eur J Cancer 37 Suppl 
4: S9-15. 
 
1 3 1 .  Sizeland AM, and Burgess AW. (1992) Anti-sense transforming growth factor alpha 
oligonucleotides inhibit autocrine stimulated proliferation of a colon carcinoma cell line. Mol 
Biol Cell 3: 1235-43. 
 
 73 
1 3 2 .  Citri A and Yarden Y. (2006) EGF-ERBB signaling: towards the systems level. Nat Rev Mol 
Cell Biol 7: 505-16. 
 
1 3 3 .  Sharma SV, Bell DW, Settleman J, Haber DA. (2007) Epidermal growth factor receptor 
mutations in lung cancer. Nat Rev Cancer 7: 169-81. 
 
1 3 4 .  Lafky JM, Wilken JA, Baron AT, Maihle NJ. (2008) Clinical implications of the 
ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Bioch 
Bioph Acta 1785: 232–65. 
 
1 3 5 .  Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, et al. (2005) A phase II trial of 
ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase 
inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 23: 165-70. 
 
1 3 6 .  Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR, Nicklee T, Ho J, Hedley D, Tsao 
M, Moore MJ, Oza AM. (2006) Phase II study of erlotinib (OSI-774) in patients with metastatic 
colorectal cancer. Br J Cancer 94: 1136-43. 
 
1 3 7 .  Bardelli A and Siena S. (2010) Molecular Mechanisms of Resistance to Cetuximab and 
Panitumumab in Colorectal Cancer. J Clin Oncol [Epub ahead of print]. 
 
1 3 8 .  Shankaran V, Obel J, Benson AB 3rd. (2010) Predicting Response to EGFR Inhibitors in 
Metastatic Colorectal Cancer: Current Practice and Future Directions. Oncologist [Epub ahead of 
print]. 
 
1 3 9 .  Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, Gil-Bazo I. 
(2007) Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What’s new? 
World J Gastroenterol 13: 5877-87. 
 
1 4 0 .  Yoon Y, Kim YO, Lim NY, Jeon WK, Sung HJ. (1999) Shikonin, an ingredient of 
Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell 
line. Planta Med 65: 532–5. 
 
1 4 1 .  Singh F, Gao D, Lebwohl M, Wei H. (2003) Shikonin modulates cell proliferation by inhibiting 
epidermal growth factor receptor signalling in human epidermoid carcinoma cells. Cancer Lett 
200:115-21. 
 
1 4 2 .  Nakaya K and Miyasaka T. (2003) A shikonin derivative, beta-hydroxyisovalerylshikonin, is an 
ATP-non-competitive inhibitor of protein tyrosine kinases. Anticancer Drugs 14: 683-93. 
 
1 4 3 .  Gumireddy K, Baker SJ, Cosenza SC, John P, et al. (2005) A non-ATP-competitive inhibitor of     
BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 102: 1992-7. 
 
1 4 4 .  Minsky M. (1961) Microscopy Apparatus. US Pat. 3,013,467. 
 
1 4 5 .  Minsky M. (1988) Memoir on Inventing the Confocal Scanning Microscopy. Scanning 10: 128-
38. 
 
1 4 6 .  Liedberg B, Nylander C, Lundstrom I. (1983) Surface plasmon resonance for gas detection and 
biosensing. Sensors Actuators 4: 299-304. 
 74 
 
1 4 7 .  Karlsson R. (1999) Affinity analysis of non-steadystate data obtained under mass transport 
limited conditions using Biacore technology. J Mol Recognit 12:285-92. 
 
1 4 8 .  Mickuviene I, Kirveliene V, Juodka B. (2004) Experimental survey of nonclonogenic viability 
assays for adherent cells in vitro. Toxicol InVitro 18: 639-48. 
 
1 4 9 .  Haigler H, Ash J F, Singer S J, Cohen S. (1978) Visualization by fluorescence of the binding 
and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad 
Sci U S A 75: 3317–21. 
1 5 0 .  Yoshimoto Y and Imoto M. (2002) Induction of EGF-Dependent Apoptosis by Vacuolar-Type 
H+-ATPase Inhibitors in A431 Cells Overexpressing the EGF Receptor. Experimental Cell 
Research 279: 118–27. 
1 5 1 .  Stenlund P, Babcock G, Sodroski J, Myszka D. (2003) Capture and Reconstitution of G-protein 
Coupled Receptors on a Biosensor Surface. Analytical Biochemistry 316: 243-50. 
 
1 5 2 .  Nice E, Lackmann M, Smyth F, Fabri L, Burgess AW. (1994) Synergies between 
micropreparative high-performance liquid chromatography and an instrumental optical 
biosensor. J Chromatogr A 660: 69-85. 
1 5 3 .  Varkondi E, Schäfer E, Bökönyi G, Gyökeres T, Orfi L, Petak I, Pap A, Szokoloczi O, Keri G, 
Schwab R. (2005) Comparison of ELISA-based tyrosine kinase assays for screening EGFR 
inhibitors. Journal of Receptors and Signal Transduction Res  25: 45-56. 
 
1 5 4 .  Zhou M, Felder S, Rubinstein M, Hurwitz DR, Ullrich A, Lax I, Schlessinger J. (1993) Real-
Time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers 
support the dimerization model for receptor activation. Biochemistry 32:  8193-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 75 
ATTACHMENT I: PhD COURSE 2007-2009, LIST OF CONGRESS PARTICIPATIONS 
 
 
1. SIB 2008, 53° SIB Symposium, Riccione, 2008 
F. Di Giorgio, C. Parolin, N. Calonghi, C. Mangano, C. Cappadone, J. Hysomema, C. Boga 
L. Masotti 
“(R)-9-HSA has a more remarkable antiproliferative effect compare to (S)-9-HSA” 
 
2. SIB 2008, 53° SIB Symposium, Riccione, 2008 
F. Di Giorgio, N. Calonghi, C. Cappadone, J. Hysomema, C. Mangano, C. Parolin, C. 
Stefanelli, M. Zini, M Voltattorni, L. Masotti 
“Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-
indolinones” 
 
3. SIB 2008, 53° SIB Symposium, Riccione, 2008 
C. Parolin, N. Calonghi, C. Cappadone, F. Di Giorgio, J. Hysomema, C. Mangano, V. 
Andrisano, J. Fiori, L. Masotti 
“Effect of an indole-derivative in human ovarian carcinoma cells” 
 
4. SIB 2008, 53° SIB Symposium, Riccione, 2008 
C. Mangano, N. Calonghi, C. Parolin, C. Cappadone, F. Di Giorgio, J. Hysomema, M.L. 
Bolognesi, C. Melchiorre, L. Masotti 
“Cytotoxicity evaluation of a polyamine-quinone library conjugates in human colon 
carcinoma cells”  
 
5. SIB 2008, 53° SIB Symposium, Riccione, 2008 
C. Parolin, N. Calonghi, M. Naldi, C. Mangano, F. Di Giorgio, J. Hysomema, C. 
Cappadone, V. Andrisano, A. Mai, L. Masotti 
“Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with 
HDACs inhibitors” 
 
6.  SIB 2008, 53° SIB Symposium, Riccione, 2008 
C. Mangano, N. Calonghi, M. Naldi, F. Di Giorgio, J. Hysomema, C. Parolin, C. 
Cappadone, A. Mai, L. Masotti 
 “Biological effects of a new class I HDAC selective inhibitor in HT29 colon cancer cells” 
 76 
7. SIB 2009, 54° SIB Symposium, Catania, 2009 
C. Cappadone, N. Calonghi, J. Hysomema, C. Parolin, G. Sartor, L. Masotti  
 “Effect of an indole-derivative in human ovarian carcinoma cells” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77 
ACKNOWLEDGEMENTS 
 
 
A very special thanks goes to Professor Lanfranco Masotti, without whose help I couldn’t have had 
the possibility to conclude this academic experience. I am grateful to Dr. Natalia Calonghi for the 
advice and guidance in the preparation of this thesis work. I particularly thank Dott.ssa Concettina 
Cappadone for advising and encouraging me in every moment during our work together. Thanks to 
Dott.ssa Carola Parolin and Dott.ssa Chiara Mangano who splendidly welcomed me as a colleague 
and became my friends. 
I would also like to thank Professor Helena Danielson, Department of Biochemistry and Organic 
Chemistry, Uppsala University, Uppsala (Sweden), for generously hosting me in her laboratory and 
Dott. Tony Christopeit for supervising my SPR work on EGF/EGFR complex.  
 
